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ABSTRACT 
Human immune deficiency virus (HIV) infection contributes to child mortality rates in South Africa . 
Investigations of newer technologies for improving early infant diagnosis of HIV in the South 
African setting could reduce child mortality as life saving treatment can be accessed early in life. 
This study investigated three technologies: a fourth generation rapid HIV test and two viral load 
(VL) platforms. 
Determine Combo (DC) is a qualitative fourth generation rapid test that is able to detect HIV 
antibodies and p24 antigen simultaneously. The performance of DC was evaluated in the field on 
samples from pregnant and postpartum women; in the laboratory, on stored samples from children 
and with the addition of heat denaturation. 
In the maternal DC study 90 (8.8%) of 1019 women tested HIV positive of whom 59 (17.1% 
prevalence) were pregnant and 31 % (4.6% prevalence) were postpartum. The sensitivity and 
specificity of the antibody component of DC on plasma was 100%(Confidence Interval (CI): 95.9-
100%) and 99.8%(CI: 99.2-99.9%) respectively. Three postpartum patients tested false positive for 
HIV antibodies (n=2) and p24 antigen (n=1). No true positive p24 antigen was detected 
DC was performed on stored samples from 182 (90%) HIV-exposed and 20 (10%) HIV-unexposed 
children aged from birth to six years. The DC HIV antibody component returned false negative 
results in 2 HIV-infected children; one clinically symptomatic and one asymptomatic aged 7 and 23 
months respectively. The sensitivity of DC HIV antibody was 100% (CI :94.3-100%) in infants aged 
6 months and younger with a specificity of 100% (CI:81.6-100%) for all ages. Of the 61 HIV-
infected infants tested , the DC p24 antigen was reactivein only one clinically symptomatic infant 
resulting in a sensitivity for detection of HIV infection of 1.7% (CI 0.3-8.9%). 
A heat denaturation technique designed to improve p24 antigen detection was applied to HIV-
infected samples but failed to enhance p24 antigen detection on DC. 
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HIV viral load (VL) molecular assays are used to confirm an HIV-infected diagnosis and for VL 
monitoring. In South Africa, plasma is the gold standard sample for VL monitoring in infants even 
though dried blood spots (OBS) are the preferred specimen type in resource-constrained settings 
and for early infant diagnosis. The use of OBS specimens for HIV VL monitoring would 
convenience resource limited settings. The OBS matrix therefore requires validation to determine 
accuracy (for establishing diagnosis) and precision (for VL monitoring) compared to plasma VL. 
This study investigated the accuracy and precision limits of OBS VL on the Roche Cobas 
AmpliPrep-Cobas TaqMan HIV-1 v2.0 assay (CAP/CTM) and the Abbott RealTime HIV-1 assay 
(m2000) platforms on samples from HIV-infected adults and children. The CAP/CTM was 
investigated on OBS containing 751J1 blood and the m2000 was investigated using one (50IJI) and 
two (2x501J1) OBS. 
Compared to plasma VL, OBS VL from adults and children were higher in the lower range 
«310g,<1000copies/ml) and lower values in the higher range (>510g, >185,000copies/ml) on the 
CAP/CTM in the study of OBS VL accuracy. Additionally, OBS VL values were >log1.0 higher in 
42/100 (42%) of adult and 16/49 (33%) of measurements from children, which will have clinical 
significance. On the m2000 platform, the differences between plasma and OBS VL were lower in 
the range >5 log and higher in the range 2 log copies/ml (100 copies/ml) to 4 log copies/ml (10000 
copies/ml). Compared to plasma VL, OBS VL values were >log1.0 higher in 20/82 (24%) adult and 
7/43 (16%) of measurements from children. 
Both platforms demonstrated 100% specificity in testing stored OBS from HIV-uninfected infants 
who were diagnosed negative on HIV DNA PCR. 
Acceptable limits for plasma VL precision is a coefficient of variation (CV) <35% and standard 
deviation (SO) :50.19 log. Where plasma VL :5510g, OBS VL demonstrated poor precision with 
CV>40% in 8/10 patients and total SO>0.30 log in 4/10 patients on the CAP/CTM. The m2000 
total SO was >210g between adult plasma and OBS VLs under the 4 log copies/ml cut-off, 
vi 
irrespective of the number of DBS used. DBS VLs were unreliable when using precision limits 
used on plasma VLs on both platforms. 
In conclusion the DC test does not offer any advantage over currently available rapid tests in 
diagnosing new infection in women and children. The two VL platforms can be used to establish 
an HIV status in treatment naive patients in view of the 100% specificity. HIV-infected patients on 
treatment with undetectable plasma VL will always have detectable DBS VL on CAP/CTM, but 
equally undetectable DBS VL on the m2000. With DBS, the CAP/CTM assay generates higher VL 
values in the lower VL range than on plasma likely due to amplification of proviral DNA. Both 
platforms display poor intra- and inter- assay precision, using plasma VL based criteria and the 
variances would potentially affect clinical decision making. The acceptable limits for plasma VL 
precision cannot be applied to DBS VL on either platform. 
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CHAPTER 1 
INTRODUCTION TO DIAGNOSIS AND MONITORING OF 
HIV IN INFANTS 
Sub Saharan Africa carries the largest burden of the global HIV pandemic. Of the 34 
million people that are HIV-infected globally, 23.5 million (69.1 %) people live in 
African countries within resource limited settings [1]. Although much progress has 
been made in the battle against HIV, challenges such as early identification of HIV-
infected pregnant and postpartum mothers in need of antiretroviral therapy (ART) 
and paediatric HIV diagnosis at point of care remain challenging issues for resource 
limited settings [2]. Mother to child transmission is the predominant source of 
paediatric HIV infection. A groundbreaking study showed that early diagnosis and 
treatment of HIV-infected pregnant women and their HIV-exposed infants reduces 
paediatric mortality [3], but access to therapy is only possible once a definitive 
diagnosis of infection is made. The World Health Organization (WHO) recognises the 
need for newer, inexpensive, straightforward tests to aid the identification , diagnosis 
and management of HIV-infected persons and has recommended that these tests be 
assessed as a research priority [4] . 
The increasing access to ART in countries that are most affected by HIV 
necessitates an expansion of appropriate testing technologies that aid early 
diagnosis of persons that have been exposed to HIV and monitoring of those who 
have been initiated on treatment. Studies of newer testing assays are necessary to 
collect enough evidence to influence practice. As such, a major drawback for infant 
testing guidelines is that commercially available rapid HIV tests are often validated 
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on adult populations [5-7] and disseminated in the field without evaluation in 
paediatric populations. Findings in adult studies may not always be applicable to 
children, which necessitates the validation of HIV rapid tests and HIV monitoring 
technologies in paediatric populations before recommendations for their widespread 
use can be made. Data on the performance of newer assays and the performance of 
new applications on existing assays could refine the current diagnostic algorithm in 
resource limited settings [4]. 
Presently, in view of ART expansion, the largest viral load (VL) laboratory in the 
world, based at the National Health Laboratory Services, Johannesburg, is able to 
provide 45 000 plasma VL results monthly. Plasma VL tests have been used to 
confirm an HIV-infected status and to monitor patient response to ART in infants in 
South Africa. VL testing on Dried blood spots (DBS) would potentially increase the 
number of monthly VL tests and consequentially raise the number of adults and 
children that gain access to life saving ART, but is not as yet approved by some 
manufacturers of VL technologies as a sample type for routine care. DBS VL as an 
alternative strategy to plasma VL testing, would benefit resource limited settings. 
Collection of plasma requires venipuncture skills whereas DBS sample collection is 
uncomplicated and addresses the lack of phlebotomy skills in healthcare workers. 
DBS transport logistics are simpler than those for plasma as DBS samples can be 
stored and transported at room temperature [8]. Plasma samples require cool 
storage if testing does not take place within 30 hours of sample collection [9] [10]. 
This study aimed to address outstanding questions that could lead to improved HIV 
care by investigating the utility of a fourth generation rapid test in identification of 
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HIV-exposed and-infected infants and pregnant women. DBS VL accuracy (for the 
diagnosis of HIV) and precision (for HIV monitoring) on two technologies was 
investigated to provide evidence for improved healthcare delivery. 
To address the objectives, the study was divided into two components: 
(1) To assess the Determine Combo HIV-1/2 Ag/Ab Combo Test (Inverness Medical, 
Japan Co., Ltd) (DC), a fourth generation rapid test in the identification of HIV-
infected mothers and their infants. 
(2) To assess the accuracy and precision limits of DBS VL testing performed on two 
VL platforms, namely, Abbott RealTime HIV-1 m2000sp/m2000rt (Abbott Molecular 
Inc, Des Plaines, USA) and COBAS AmpliPrep/COBAS TaqMan version 2.0 (Roche 
Molecular Systems, Branchburg, NJ). 
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CHAPTER 2 
DETERMINE COMBO RAPID TEST STUDY 
12.1 INTRODUCTION 
Early diagnosis of HIV in infants is imperative for the infant to access life-saving ART 
[3] and for monitoring the efficacy of Prevention of Mother to Child Transmission 
(PMTCT) programs. This is a dynamic field in which questions of how best to deliver 
quality, affordable diagnostics are constantly raised by WHO [11] to assist countries 
such as South Africa in reducing maternal and paediatric HIV-related mortality. 
South African child and maternal mortality attributable to HIV was 35% and 43% 
respectively and an estimated 1.3 million children were maternal orphans in 
2011 [12]. The Global Plan towards elimination of new HIV infections among children 
by 2015 and keeping their mothers alive campaign lists South Africa as one of the 22 
countries for the reduction of new childhood infection by 90% and the number of 
maternal deaths by 50% [2]. It is therefore important to identify HIV-infected women 
and children for treatment at their first contact with health care services [4] , by 
testing for acute and established diagnosis with enhanced, affordable and sensitive 
rapid tests. 
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2.1.1 BIOLOGICAL CHARACTERISTICS OF HIV INFECTION 
Persons newly infected with H IV experience an acute phase of infection which is 
characterised by high titres of virus in peripheral blood and associated with 
increased transmission rates [13]. Diagnosis of HIV in the acute phase of infection 
can be made by the detection of HIV viral antigens. p24 antigen (Ag), a structural 
protein from the core of the HIV virus, is the earliest detectable marker of HIV 
infection and is detectable in blood 16 days after exposure (Figure 2.1). Viral p24 Ag 
levels are at the highest at the beginning of infection and in late stage disease [13]. 
In both instances HIV antibodies (Ab) are absent or present in low titres respectively 
allowing the p24 Ag to exist unbound from the HIV Ab. 
Production of HIV Ab marks the end of the window period, the interval between HIV-
exposure and the production of HIV Ab. HIV Ab are proteins produced by the host 
immune system in response to the HIV virus 21 days after HIV-exposure in a 
process called seroconversion (Figure 2.1) [14]. The formation of the HIV Ab and 
p24 Ag immune complex renders p24 Ag undetectable [15]. 
HIV Ab detection is adequate to establish an HIV-infected diagnosis in adults and 
children over 18 months of age. However, testing for HIV infection in children 
younger than 18 months of age differs from that for older children. Infants born to 
HIV-infected mothers (also referred to as HIV-exposed infants) acquire maternal HIV 
Ab that may remain detectable in the infants bloodstream until 18 months of age. 
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Therefore, HIV Ab detection in infants younger than 18 months of age is indicative of 
the HIV-exposure status and not the HIV-infection status of the infant [16]. 
Laboratory viral detection tests remain the gold standard for diagnosis in infants 
younger than 18 months of age [11]. 
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Figure 2.1: Kinetics of HIV markers during early infection [14] 
2 .1.2 SCREENING AND CONFIRMATORY HIV TESTING 
2.1.2 .1 HIV Ab DETECTION ASSAYS 
Assays that detect HIV Ab (e.g. Enzyme-linked immunosorbent assay (ELISA) and 
rapid tests) are simple, accurate tools for HIV diagnosis. Rapid tests have expanded 
the opportunity to screen and test for HIV infection in adults and infants older than 18 
6 
months of age in resource limited settings at point of care as they do not require any 
special instrumentation or phlebotomy skills and provide an advantage over 
laboratory tests in that the patient receives the test result on the same day at a single 
clinic visit. The WHO recommends that rapid tests used for screening have 
sensitivity and specificity of >99% and >98% respectively [11] for accurate 
screening in the field (Table 2.1). 
HIV Ab detection on rapid tests is indicative of HIV-exposure in infants younger than 
18 months but prompts further virological testing to establish the infection status in 
the infant [17]. Presently available third generation rapid tests cannot detect 
components of the HIV virus and are superseded by laboratory fourth generation 
ELISA which are HIV Ab and HIV virus detecting assays. 
Limitations of currently available third generation rapid tests in ill , symptomatic 
persons who have been documented to have low or undetectable HIV Ab levels, is 
the risk of a false negative diagnosis. An additional limitation of third generation HIV 
rapid tests is that individuals with acute infection will be missed for diagnosis as the 
test is limited to HIV Ab detection [18]. 
Efforts have been made to develop rapid tests for viral detection [19] to aid the 
diagnosis of HIV in children. 
2 .1.2.2 VIRAL DETECTION ASSAYS 
Viral detection assays such as DNA and RNA Polymerase chain reaction (PCR) and 
p24 Ag assays that detect components of the HIV virus are the benchmark for 
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diagnosing HIV infection in children younger than 18 months of age [11, 16]. 
However, the cost and infrastructure requirements for viral detection assays render 
them less suitable for resource limited settings [11]. 
Although p24 Ag assays have a specificity of 100% , they are used less commonly 
than DNA and RNA assays for diagnosing HIV because their sensitivity is very low at 
around 50% [20] (Table 2.1). The reason for this is that p24 Ag binds to HIV Ab in an 
immune complex that prevents detection of p24 antigen. Heat dissociation or acid 
denaturation has been used to disrupt the immune complex thereby increasing the 
sensitivity of the p24 Ag detection [15, 21]. Ultrasensitive p24Ag assays have a 
much improved sensitivity as compared to the earlier p24 Ag assays but are not 
readily commercially available [22, 23]. 
Table 2.1: Summary of laboratory tests that are used to diagnose HIV in children 
and their general performance characteristics [11] 
HIV viral detection assays 
<18 months of age 
RNA and DNA peR assays 
Sensitivity >98% 
Specificity >98% 
p24 Ag assays 
Sensitivity ± 50% in children 
Specificity ± 100% 
Ultrasensitive p24 Ag assays 
Sensitivity ±96% in children <6 
weeks of age 
Specificity ± 1 00% 
*HIV Ab detection assays 
> 18 months of age 
ELISA (third and fourth generation) 
and rapid tests 
Sensitivity >99% 
Specificity >98% 
*Detect HIV-exposure, not HIV infection in children younger than 18 months of age [16]. 
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2.1.3 IDENTIFICATION AND TESTING OF PREGNANT WOMEN AND 
CHILDREN IN SOUTH AFRICA 
South Africa's PMTCT (Prevention of Mother to Child Transmission) programme 
utilizes the provider-initiated counselling and testing strategy for screening patients 
[24]. The current South African PMTCT guidelines recommend that pregnant women 
should be tested at their first antenatal clinic visit and between 32- 34 weeks of 
pregnancy if their initial HIV test was negative [25] thereby expanding the search for 
identifying mother and baby pairs in need of prophylactic care [26]. 
Patients are tested on a rapid test and considered to be HIV-uninfected if the test is 
negative. If the rapid test is positive, a second, different rapid test is used to confirm 
the HIV-infected status. Laboratory HIV ELISA tests are used to resolve discordant 
rapid test results [24]. The Western Blot assay can be used to confirm a reactive 
ELISA result as the test is designed to detect specific HIV proteins. The test can also 
be used to rule out false positive ELISA results. Western blot tests are not requested 
routinely as they are difficult to perform and require technically skilled staff. 
In line with the National Department of Health's (DoH) policy to eradicate paediatric 
HIV infection, women at the Rahima Moosa Mother and Child Hospital (RMMCH) in 
Johannesburg, South Africa are offered a further opportunity to establish their HIV 
status by means of a third generation HIV rapid test immediately postpartum if their 
HIV status is unknown and if more than six weeks have passed since their last 
negative HIV test result [26]. The relevance of repeating the test after 6 weeks is to 
accommodate the window period. Currently available third generation HIV rapid tests 
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are limited to HV Ab detection. Women with acute HIV infection in the window period 
will test negative on the third generation HIV rapid tests as they have no HIV Ab at 
the window stage of infection. HIV viral antigens peak during the window period and 
the risk of MTCT through birth or breastfeeding is increased [13, 27]. Efforts are 
underway to develop sophisticated point of care tests for diagnosis of acute infection 
(by detection of HIV Ag during the window period) [14, 28, 29]. Theoretically, an HIV 
Ag detecting point of care test would enable women to learn their HIV status during 
the period in which they are hyper infectious, enabling appropriate, early treatment 
intervention. 
The significance of re-testing pregnant women has been demonstrated by studies in 
which 1.3% and 3.4% of women who tested HIV negative at their first antenatal visit, 
subsequently seroconverted during pregnancy or within a year after delivery[30, 31]. 
A Kenyan study showed that 2.6% (53/2035) women contracted the HIV infection 
between pregnancy and the 6-week post partum period demonstrating the potential 
risk of infant HIV infection between delivery and the first postnatal visit [32]. 
HIV-exposed babies are largely identified for prophylaxis though PMTCT 
programmes that have identified the mother to be HIV-infected [26]. These HIV-
exposed babies that are younger than 18 months of age cannot be tested on 
currently available HIV Ab detection assays to establish their HIV-infection status as 
the assays cannot differentiate between maternal and infant HIV Ab [16]. During 
early HIV infection in infected infants, maternal HIV Abs are present to complex with 
p24 Ag hindering p24 Ag detection. As maternal HIV Ab wane (process of 
10 
seroreversion), increasing infant HIV Ab titres participate in immune complex 
formation. In advanced disease, HIV-infected infants with hypogammaglobulinaemia 
(including low HIV Ab titres), high viral loads and waning maternal HIV Ab are the 
likeliest to have uncomplexed, detectable p24 Ag [20]. Studies have shown the 
seroreversion process to begin as early as 3 months [33]. Whilst maternal HIV Ab 
wane, HIV infected infants will produce their own HIV Ab and have high levels of p24 
Ag as a result of viral replication. The balance of p24 Ag relative to HIV Ab may 
change in favour of more unbound and therefore detectable p24 Ag. As a result, the 
sensitivity of p24 detection assays may increase during the period that maternal HIV 
Ab wane [20, 34]. 
The WHO guidelines on infant HIV testing recommends that all HIV-exposed infants 
are tested at 4 to 6 weeks of age by a DNA peR test [11]. The peR test results are 
communicated to the caregiver at the infants 10 week immunisation visit. The lag 
between the initial laboratory peR test and initiation of Highly Active Antiretroviral 
Therapy (HAART) results in the initiation of therapy around eleven weeks of age for 
HIV-infected infants [35] even though it has been established that ART initiated at a 
median of seven weeks of age reduces infant mortality by 75% [3]. Early diagnosis 
and initiation of treatment would be enhanced if a rapid test, at point of care, could 
potentially identify HIV-infected children presenting with illness and clinical features 
of HIV. At present there are no rapid tests that provide a definitive HIV infected 
diagnosis for use in children younger than 18 months. Infants in resource limited 
settings where laboratory viral detection assays are unavailable are further 
disadvantaged and would benefit from such a rapid test. More expensive and 
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complex point of care units that aid the early diagnosis of infants are being 
developed and evaluated [29], but are not yet available. 
2 .1.4 THE FIRST FOURTH GENERATION POINT OF CARE TEST FOR HIV 
DIAGNOSIS 
The Determine Combo HIV-1/2 Ag/Ab Combo Test (DC) (Inverness Medical , Japan 
CO.,Ud) is the first fourth generation rapid test. [36]. It surpasses third generation 
tests by providing simultaneous differentiated HIV Ab and p24 Ag detection in a 
single test [19] . The DC rapid test is reported to have the potential to diagnose HIV 
infection five days (range 2-20 days) earlier than third generation rapid tests [36]. 
The DC test expands the diagnostic spectrum by identifying persons during the 
acute phase of infection; the phase in which p24 Ag unbound to HIV Ab is detectable 
[7]. The DC test does not require refrigeration making it easier to use in low resource 
environments. 
Potential advantages of the DC test over current third generation rapid tests in 
pregnant women are that newly infected women in the window period will test p24 
Ag positive and their infants, at high risk of acquiring HIV during an acute maternal 
infection , will be identified for intervention. A disadvantage of using DC over third 
generation rapid tests is its higher cost. 
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The theoretical advantages of the DC test being able to detect p24 Ag in children 
include an earlier definitive diagnosis of HIV infection and more reliable identification 
of children with late stage HIV infection who may have very low levels of HIV Ab 
known to result in false negative third generation rapid tests [37]. The DC test 
therefore has the potential to act as the first point of care test for a definitive 
diagnosis of HIV infection in children aged less than 18 months in resource limited 
settings. If the sensitivity of DC for detecting p24 antigen is the same as earlier 
laboratory p24 antigen assays, then the DC rapid test may correctly diagnose a 
positive HIV infection status in 50% of HIV-exposed, infected infants [20]. Assuming 
the sensitivity of HIV Ab detection in DC is >99% (like third generation rapid tests), 
then it may be a useful tool for the identification of HIV-exposure in infants and HIV-
infection in children older than 18 months of age. 
The reported sensitivity and specificity of the DC Ab component is 100% (95% CI 98-
100) and 100% (95% CI 98.2-100) respectively and the sensitivity of the p24 Ag 
component is 86.6% (95% CI 76-93.7) on DC by using samples that were collected 
in the window period [38]. The specificity of DC p24 Ag was 96.6% as reported by 
the manufacturer [36]. No sensitivity for p24 Ag detection in established HIV infection 
is reported. 
The performance of the DC in 40 HIV-infected infants aged 3-months or less 
demonstrated a sensitivity for HIV Ab detection of 100% (95% CI 95.9-100%) and for 
p24 Ag detection of 2.5% (95% CI 0.1-14.7%) [39]. No clinical details on the single, 
3-month old infant identified as infected by the DC p24 Ag were recorded. No data 
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on the performance of the DC test in older infants and children are available 
particularly to assess whether it may be useful in specific clinical scenarios such as 
advanced disease. The DC test has not been widely assessed in children. 
2 .1.5 AIMS AND OBJECTIVES 
This study evaluated the performance of the first fourth generation rapid HIV test in a 
1. prospective maternal evaluation 
- in pregnant women for detecting early infection (by p24 Ag detection) and 
established infection (by HIV Ab detection) in order to identify HIV-infected women. 
2. retrospective paediatric evaluation 
- in children for detecting HIV-infection and HIV-exposure on stored 
samples from children of varying ages and clinical scenarios 
A small subset of maternal and paediatric samples were evaluated to assess 
whether heat denaturation increased the sensitivity of p24 Ag detection by the DC 
test. 
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12.2. MATERIALS AND METHODS 
The study has been described in three sections The prospective study assessed the 
performance of the DC rapid test on pregnant women at a clinical site. The 
retrospective component describes the testing of stored paediatric samples on the 
DC test. Section 3 is a heat denaturation study of stored samples from Sections 1 
and 2 (figure 2.2). 
Fourth generation DC rapid HIV test 
Prospect ive Study (Mat ernal) 
Section 1 
Field invest igat ion: 
St udy of pregnant and postpa rtum 
women: 
n = 1019 plasma; 
subset 380 whole blood 
reference standard: 3rd generation 
Aeon and Advanced qua lity rapid tests 
for DC HIV Ab detection. 
Viral detect ion assays for DC p24 Ag 
detection 
Restrospective Study (Paediatric) 
Section 2 
Laborat ory investigation of st ored 
paediatri c samples: 
n = 202 samples from HIV exposed-
in fected; exposed uninfected an d 
unexposed chi ldren f rom ages birth to 
6 years. 
reference standard: laboratory HIV 
ELISA and DNA peR 
Section 3 
Laboratory invest igat ion :p24 ant igen heat denat uration study: 
n = samples from 6 adult and 9 infants tested usjng 38 DC test strips 
reference standard: HIV DNA PCR and laborato ry ELISA and var ious rapid test s 
Figure 2.2: Flow diagram presentation of the components of the rapid test study 
section . 
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Ethics approval (M091133) to conduct this study was granted by the Human 
Research Ethics Committee at the University of the Witwatersrand, Johannesburg 
(Appendix A). 
2 .2.1 SECTION 1: MATERNAL DC STUDY 
The study was conducted at RMMCH, situated in the west of Johannesburg in the 
Gauteng province. This tertiary hospital provides health care services, including 
PMTCT, for women from the surrounding geographical area. The number of 
deliveries at RMMCH annually [26] were considered adequate to enrol the sample 
size required for this study within a reasonable time period. The convenience of 
having the antenatal clinic and delivery ward in close proximity of each other at 
RMMCH facilitated the enrolment of pregnant and postpartum patients for the study. 
Women attending the antenatal clinic and delivery ward were invited to participate in 
the study. 
The medical staff at the study site consisted of two counsellors, two phlebotomists, a 
principal medical officer and two medical technologists. The latter were responsible 
for performing and documenting the routine HIV tests and the fourth generation rapid 
tests. The counsellors interviewed the participants, provided pre- and post-test 
counselling and documented whether women verbally reported or had documented 
evidence of their HIV status and when they last had an HIV test. Women with an 
unknown or reported negative HIV status as well as those with a documented HIV 
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negative result performed more than six weeks previously were invited to participate 
in the study. Women who reported an HIV positive status but had no supporting 
documentation were also invited to retest. Women that had documented evidence of 
their HIV-infected status were excluded . Written informed consent was obtained from 
all participants who agreed to test for HIV. 
2.2.1.1 SAMPLE SIZE 
The Centers for Disease Control and Prevention (CDC) guidelines for prospective 
evaluation of HIV testing technologies recommend that 200 HIV-infected and 200 
HIV-uninfected plasma samples be included in the test evaluation to provide 95% 
confidence intervals for the calculation of sensitivity and specificity [40] . The total 
number of samples to be included in the study depended on the HIV prevalence 
within the test settings [40]. The prevalence of HIV amongst pregnant women testing 
antenatally and postpartum at RMMCH was 15% and 4% respectively in 2008 [26]. It 
was estimated that a total of 1450 patients would need to be enrolled in the study to 
meet the CDC guidelines and it was anticipated to take six months to achieve based 
on RMMCH records that showed that approximately 200 women presented for 
testing monthly (unpublished). 
In order to assess the performance of the DC test on whole blood as compared to 
plasma, a subset of the 1450 samples was tested on both plasma and whole blood , 
until 20 HIV:infected and 80 HIV-uninfected DC tests results were obtained on whole 
blood . 
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In addition to the calculation of sample size for overall infection rate the number of 
incident (number of newly diagnosed cases of HIV over a period of time) infections 
that could be expected at RMMCH site was calculated. The number of newly 
diagnosed cases of HIV over a period of time (incidence) at RMMCH for the first 
antenatal HIV test is not known. Repeat testing of HIV-negative women at the time of 
delivery [26], demonstrated that 4.5% seroconverted confirming that incident 
infections do occur. South African women aged 20-39 years had an HIV incidence of 
±3 - 5.6% per annum [41] with higher rates expected in pregnancy. It was expected 
that over a 6-month period, approximately 1.5 - 2.8 cases of newly infected women 
would be detected per 100 HIV-uninfected women tested. In a sample size of 1250 
HIV-uninfected women (assuming that 200 women out of 1450 would be HIV-
infected), 18-35 incident or early HIV infections would be diagnosed by DC as p24 
Ag positive and HIV Ab negative. If incident infection rate over 6 months was 1 % 
then in 1250 postpartum women, 13 newly infected women should be detected by the 
fourth generation DC test. 
The number of new infections detected by the DC test in this study would provide 
information on how many new cases of HIV infection in pregnant women could be 
detected every six months at the RMMCH service. 
2.2 .1.2 HIV TESTING PROCEDURE 
Five millilitres of whole blood was collected into an Ethylenediaminetetraacetic acid 
(EDT A) tube for testing at a laboratory located at RMMCH study site. The single 
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EDTA tube was used for the routine HIV rapid tests as well as for the study to avoid 
drawing extra blood from the patient. Whole blood was separated into two equal 
aliquots and labelled with the patient name and laboratory reference number. One 
aliquot was centrifuged at 3000rpm for five minutes to obtain plasma. Third 
generation rapid tests Advance Quality HIV rapid test (In Tec Products, Inc. Xianen, 
China) and Acon HIV 1/2/0 Tri-line Rapid Test Device (Acon Laboratories, Inc. , San 
Diego, USA) were the tests stipulated by the DoH for use in the National testing 
program and were performed according to Figure 2.3 with the DC test performed in 
parallel on plasma. A subset sample of DC tests were conducted on whole blood in 
addition to plasma. Whole blood testing required the use of a chase buffer. 
National Testing Algorit hm 
Discordant Re;ull 
T'e B<eJ~.er eg. 
laboratory HIV 
EUSA to establish 
~t atus 
Study 
Figure 2.3: The Determine Combo rapid test was performed in parallel with the 
routine algorithm [42] 
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2.2.1.3 INTERPRETATION OF TEST RESULTS 
The DC is a qualitative immunochromatographic test presented in a lateral flow 
device for use on plasma, whole blood or serum that takes 20 minutes to perform 
and is read visually. Each test strip incorporates a procedural positive control and the 
test is considered valid only if the positive control is detected [36]. The test strip is 
divided into an HIV Ab window and an HIV p24 Ag window (Figure 2.4). The 
presence of a pink line in the p24 Ag or HIV Ab windows was indicative of HIV 
infection (Figure 2.4). The DC HIV Ab test principle is based on the binding of HIV 
Ab (if present) to an antigen selenium colloid and recombinant antigen to form the 
pink line in the HIV Ab window. The p24 Ag detection is based on the binding of 
unbound p24 Ag to a biotinylated and selenium colloid anti-p24Ab and immobilised 
avidin to form a pink line in the HIV p24 Ag window [36](Figure 2.4). 
The four hour turnaround time between pre-test counselling , sample collection, rapid 
testing and post test counselling ensured that women received their test results 
within the day. 
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control 
p24Ag 
IllVAb 
A B C D E 
I nterpretatio n: 
• A: Negative 
• B: HIV Ab and p24Ag positive 
• C: p24 Ag positive 
• D: HIV Ab positive 
• E: Invalid 
Figure 2.4: Interpretation of DC test results. The DC test strip comprises the control, 
p24 Ag and HIV Ab windows. Pink lines represent a valid test and an HIV positive 
result. Interpretation of results of the HIV Ab and p24 Ag components of the DC rapid 
are described from test strips A-E. 
Patients that tested HIV positive on the routinely used third generation rapid tests 
were referred to ARV clinics. Where the third generation rapid test results were 
discordant, samples were referred for a confirmatory laboratory fourth generation 
ELISA (ARCHITECT® HIV Ag/Ab Combo assay; Abbott Diagnostics; Wiesbaden, 
Germany) and disclosure of the patient's HIV status was delayed (Figure 2.3). The 
results from DC did not influence the diagnosis of the patient even if p24 Ag was 
detected and the third generation Advanced quality screening test was negative 
because the DC test was under validation. The DC p24 Ag test results were kept 
confidential and not disclosed to the patient unless an HIV-infected status was 
confirmed by additional viral detection assays, in which case the patient was 
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contacted for retesting . Samples that tested p24 Ag positive on DC were verified with 
a p24 Ag detection assay (Vironostika HIV-1 Antigen ; bioMerieux; Bosiend, The 
Netherlands) and a viral load test (NuciiSens EasyQ-EasyMag HIV-1, version 1.2 
assay; bioMerieux; Boxtel, The Netherlands). Plasma remaining from routine testing 
was stored at -20°C at the RMMCH facility for 48 hours and subsequently shipped to 
an accredited storage facility for long term storage at -80°C to enable further testing 
in cases where the laboratory gold standard HIV ELISA or viral detection assays 
yielded discordant results or in cases of misplaced samples and laboratory 
accidents. 
2 .2.1.4 STATISTICAL ANALYSIS 
Descriptive statistical analyses including sensitivity (true positives / (true positives + 
false negatives) , specificity (true negatives / (true negatives+ false positive) , positive 
and negative likelihood ratios (LR) were used to evaluate the performance of DC in 
detecting established and new HIV infections in women. Sensitivity described the 
probability of a positive rapid test when HIV is truly present. Specificity refers to the 
probability of a negative test result when HIV is truly absent. The LR were calculated 
instead of predictive values because predictive values depended on prevalence and 
a difference in HIV prevalence was anticipated between women tested in the 
antenatal and postpartum period . A positive LR (sensitivity/(1-specificity)) >10 
strongly predicts HIV-infection, whereas a negative LR ((1-sensitivity)/specificity) 
<0.1 virtually excludes the condition. 
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2.2 .2 SECTION 2: PAEDIATRIC DC STUDY 
This component of the study used stored paediatric samples from prospective 
longitudinal [43] and cross sectional study cohorts enrolled in 2002 and 2005 [44] 
respectively. Clinical data records were reviewed for sample selection. Criteria for 
inclusion were dependent on the child's age, HIV-exposure and -infection status, 
CDC clinical disease stage and a minimum volume of 501-11 sample being stored. 
The CDC system of classification categorises patients on the basis of conditions 
associated with the HIV infection and assists clinicians to stage the infection. For the 
purposes of this study, children classified as CDC clinical stage A and N were 
considered clinically asymptomatic whilst those classified as CDC clinical stage B 
and C were considered clinically symptomatic [45]. This study attempted to model 
real-life circumstances of children presenting for testing in the field by using four 
clinical scenarios, namely: 1) H IV-exposed , -infected and clinically asymptomatic 
(CDC A and N) children; 2) H IV-exposed , -infected and clinically symptomatic (CDC 
B and C) children; 3) HIV-exposed uninfected children and 4) HIV-unexposed 
children. Expected outcomes for the DC HIV Ab and p24 Ag components in the 
various ages and clinical scenarios are detailed in (Table 2.2). The ages of the 
children chosen for this study ranged from birth to six years (Table 2.3). 
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Table 2.2: Anticipated DC test results based on age, HIV status and clinical stage. 
Clinical scenario 
HIV-exposed, HIV-infected, 
asymptomatic 
HIV-exposed, H IV-infected , 
symptomatic 
HIV-exposed, HIV-uninfected 
HIV-unexposed, HIV-uninfected 
Determine Combo HIV Ab result Determine Combo p24Ag result 
Positive at all ages 
Positive at all ages # 
Positive in < 18 months of age II 
Negative in ~ 18 months of age 
Negative at all ages 
Positive in ±50% * 
Positive in ±50% * 
Negative in <18 months of age 
Negative in ~18 months of age 
Negative at all ages 
* more than 50% of infants may be detected if the p24 Ag/ Ab balance is in favour of unbound p24 Ag during the time that 
maternal HIV Abs wane, infant HIV Ab production increases and viral replication is unchecked 
# in severely symptomatic infants with hypogammaglobulinaemia, HIV Abs may be undetectable however, the DC p24 Ag should 
be positive and avoid the false negative results of the current third generation rapid tests 
" older infants and children may serorevert earlier and test HIV Ab negative before 18 months of age. Together with a negative 
p24 Ag test, HIV infection can be excluded (in the absence of breastfeeding) 
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All children had a prospectively determined HIV status with documented HIV Ab and 
viral detection assay results. The reference standards against which the DC results 
were measured were the Roche Amplicor HIV-1 DNA version 1.5 (Roche 
Diagnostics Systems, Inc., Branchburg, NJ) viral detection assay for the ability of the 
DC p24 Ag component to diagnose infection; and the HIV-1/HIV-2111 Plus, IMx 
System (Abbott Diagnostics Division, Wiesbaden, Germany) third and fourth 
generation ELISA Ab detection assays and rapid tests (Table 2.3) for the ability of 
the DC Ab component to diagnose HIV-exposure in infants <18 months of age and 
HIV- infection in older children. 
2.2 .2.1 SAMPLE SIZE 
The paediatric samples available for testing were collected six to nine years prior to 
this study. The scarcity of such samples from children hampers the ability to test 
larger sample sizes unless large multicentre studies are conducted over long periods 
of time. A convenience sample of 202 infants that had a minimum stored sample 
volume of either serum or plasma of 501-11 , required to perform the DC test, were 
retrieved from -80 e C storage in an accredited laboratory. Preference was given to 
samples from each of the studies that fulfilled the criteria for the different clinical 
scenarios and had the most age-appropriate HIV test results available for 
comparison (Table 2.3). 
2.2.2 .2 HIV TESTING PROCEDURE 
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n 
77 
125 
Samples were retrieved from storage, thawed once in batches at room temperature, 
centrifuged at 3000 rpm for 5 minutes and tested over two days in an accredited 
laboratory and by a single operator in accordance with manufacturer instructions. 
Table 2.3: Paediatric samples tested on DC. Samples were selected from two 
prospectively conducted studies in which children's HIV infection status was 
determined by age-appropriate H IV tests. 
study Reference assay for DC HIV Ab and p24 Age Ag result comparison 
HIV Ab detection Viral detection 
* ELISA and rapid 6-weeks, 3, 7-Longitudinal cohort 
tests 00 
DNA PCR 
12 months 
Cross-sectional cohort 
ELlSA*t and rapid 
DNA PCR Birth to 6 00_ 
tests years 
*Third generation ELISA HIV-1IHIV-2111 Plus, IMx System (Abbott Diagnostics Division, Wiesbaden, Germany 
OOPareekshak HIV-112 Triline Card (Bhat Biotech , Bangalore, India); Insti HIV-1 RT (BioLytical Laboratories, 
British Columbia, Canada); Smart Check (Globalmed, Vancouver, USA); First response HIV card 1-2.0 (Premier 
Medical Corporation , Daman, India); Determine™ HIV- 112 (Abbott Laboratories, Illinois, USA) 
tFourth generation ELISA HIV-1IHIV-2 III Plus, IMx System (Abbott Diagnostics Division, Wiesbaden, Germany 
-UniGold (Trinity Biotech , Co Wicklow, Ireland) 
2 .2.2.3 STATISTICAL ANALYSIS 
The statistical analyses were essentially the same as those conducted in section 
2.2 .1.4. The sensitivity, specificity, positive and negative LR of the DC Ab and p24 
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Ag component were calculated to determine the ages and clinical scenarios in which 
the DC test may add value to clinical practice. 
2.2.3 SECTION 3: p24 Ag HEAT DENATURATION STUDY 
Maternal and paediatric samples were used to investigate whether heat denaturation 
would improve the sensitivity of p24 Ag detection by the DC test. Using a technique 
described by Schupbach [15], samples were boiled to dissociate the HIV Ab and p24 
Ag immune complex and enable detection of free p24 Ag [15]. Although the 
requirement for heat denaturation is not ideal for a point of care test, boiling of 
samples could conceivably be achieved in resource-constrained environments if p24 
Ag detection was increased by this method and thereby aid the diagnosis of acute 
infection in the field. 
2 .2.3 .1 SAMPLE SIZE 
A convenience sample of six adult and nine infant samples from HIV-infected 
individuals were retrieved from storage for this exploratory study. 
2 .2.3.2 HIV TESTING PROCEDURE 
Samples from HIV-infected women and children, known to be HIV Ab positive, were 
retrieved from -8GoC storage and thawed at room temperature. The samples had 
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tested positive on the Acon and Advanced Quality rapid tests (Figure 2.3) and on 
laboratory HIV ELISA tests (Table 2.3) respectively. 
The reference standard used for detection of p24 Ag was the high positive quality 
assurance control from the HIV p24 Ag kit (Preci Control PC HIV-3 Roche 
Diagnostics GmbH, Mannheim, Germany) which was used to measure the accuracy 
of HIV p24 Ag detection in an automated ELISA test. The control was tested neat on 
the DC test prior to boiling and subsequently boiled undiluted and in 1:3 and 1:6 
dilutions for testing on DC to assess the sensitivity of the DC p24 Ag component. 
Heat denaturation in maternal samples was investigated in dilution . Distilled water 
was used to make 1:3 and 1:6 dilutions of maternal plasma in 1.5ml Eppendorf 
tubes. The serum and plasma samples from children were not diluted as there was 
insufficient volume for multiple tests. Samples from mothers and children were boiled 
in a water bath at 100°C for 5-7 minutes to disrupt the HIV Ab and p24 Ag immune 
complexes and cooled on the bench for 10 minutes [15]. Thereafter 501-11 of the heat 
denatured samples were pipetted onto the sample pad of the DC rapid test strip and 
the result was read within 20 minutes. 
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12.3 RESULTS 
2.3.1 SECTION 1: MATERNAL DC STUDY 
Of the 1099 pregnant and postpartum women that registered for care at RMMCH 
over the six month study period March to August 2010,1019 (92.7%) participated in 
the study. Enrolment of the original sample size of 1450 women including 200 HIV-
infected women was therefore not achieved. This resulted from a policy change at 
RMMCH during the study period to down refer antenatal cases to clinics. Therefore, 
most women were tested postpartum and had a lower HIV prevalence rate than 
women tested antenatally. 
Of the 1019 participants, 345 (33.9%) were pregnant and 674 (66.1 %) were 
postpartum. Ninety of the 1019 patients (8.8%) tested HIV Ab positive on the routine 
third generation rapid tests. Among these 90 HIV positives, 59 (65.5%) were 
pregnant and 31 (34.4%) were postpartum. The antenatal and postpartum HIV 
prevalence was 17.1% and 4.6% respectively. 
The DC rapid test was performed on plasma samples of all 1019 participants and on 
whole blood samples on a subset of 380 women. A total of 1399 valid test results 
were obtained as the positive control was visible on all the test strips. 
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The overall sensitivity of DC HIV Ab component was 100% in the antenatal and 
postpartum populations on plasma and whole blood (Table 2.4) . This parameter may 
have been affected by the reduced sample size of 90 instead of 200 patients [40] 
and it is possible that enrolling more patients may have reduced the sensitivity 
and/or narrowed the 95% confidence intervals. 
The specificity of DC HIV Ab was 100% (CI : 95.9-100%) on whole blood and plasma 
in the antenatal population but lower at 98.9% (CI: 96.4-99.7%) on whole blood and 
99.6% (CI : 98.8-99.9%) on plasma in the postpartum population (Table 2.4). 
There were a total of three women with false positive results on the DC assay. All 
were in the postpartum group and all false positive results occurred in both plasma 
and whole blood samples. The Acon and Advanced quality tests for these three 
women were negative whereas DC was positive for HIV Ab (n=2) and p24 antigen 
(n=1). Results from the laboratory fourth generation ELISA, laboratory p24 Ag assay 
and viral load test results confirmed that the patients were HIV uninfected. Not a 
single new or early HIV-infection was detected considering that the DC would 
provide a major advantage over other rapid tests by p24Ag detection. The DC p24 
Ag band was not detected in any of the 90 HIV-infected women tested nor in any 
previously uninfected women tested . 
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Table 2.4: Performance of the fourth generation DC on whole blood and plasma from 
pregnant and postpartum women [42]. 
sample N Prevalence DCAb+1 Sensitivity% 95% DCAb-1 Specificity% 95% 
type HIV+ (95% CI) LR+ HIV- (95% CI) LR-
Antenatal 
plasma 345 17.1% 59/59 100(93.8-100) 569.2 286/286 100(98.6-100) 0 
whole 151 59/59 100 (93.8-100) 184.5 92/92 100(95.9-100) 0 
blood 
Postnatal 
plasma 674 4.6% 33/31* 100(88.9-100) 321 .5 641/643 99.6(98.9-99.9) 0 
whole 229 32/30* 100(88.6-100) 99.5 197/199 98 .9(96.4-99.7) 0 blood 
'False positives were obtained in two women on both sample types 
The third generation and fourth generation rapid HIV tests performed equally in 
diagnosing 31 (4.6%) HIV positive cases in these 674 women (Table 2.5). There 
were 505 postpartum women who had tested HIV negative 6 -12 weeks prior to 
testing in this study (Table 2.5). Of the 505,12(2.4%) were HIV positive upon 
retesting. This reflects an incidence rate of 2.4% over the 12 week period. Despite 
these new infections occurring in the postpartum population, the DC test did not 
detect any new HIV infections i.e. no DC test returned a positive p24 Ag and 
negative Ab DC test result. Of the 674 postpartum women that participated in the 
study, 4 women reported being HIV infected but had no documented evidence of HIV 
testing. Half of the women reporting a positive HIV status (without documentation) 
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were HIV uninfected. A much higher seroprevalence in the 'unknown HIV status' 
category was documented as 24% of women were HIV-infected [42]. 
Table 2.5: HIV status of postpartum women prior to enrolment and after testing with 
the National testing algorithm and the DC test [42]. 
Reported or documented HIV status HI V- HI V- % n infected uninfected Positive 
Tested HIV negative 6-12 weeks before the study 505 12 492 2.4 
Tested HIV negative >12 weeks before the study 107 3 104 2.8 
Unknown HIV status 58 14 43 24.1 
Positive: reported but not documented 4 2 2 50.0 
Total 674 31 641 4.6 
2.3.2 SECTION 2: PAEDIATRIC DC STUDY 
Plasma samples from 202 infants, 182 (90%) HIV-exposed and 20 (10%) HIV-
unexposed, were tested using DC. Of the 182 HIV-exposed infants, 121 were HIV-
uninfected and 61 (33.5%) were HIV-infected with documented HIV ELISA and DNA 
PCR results. The HIV prevalence in this study of 202 infants was 30.2% (Table 2.6). 
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The HIV Ab component of DC demonstrated 100% specificity as no false positive 
results were obtained in the samples from the HIV-unexposed children born to HIV-
uninfected mothers (Table 2.6). 
The sensitivity of the DC Ab component varied across the age categories. DC 
achieved 100% sensitivity in detecting HIV Ab in infants younger than six months old 
(Table 2.6) . 
In contrast, a lower DC Ab sensitivity was obtained in infants older than 6 months 
because the DC Ab test results were inconsistent with the third and fourth generation 
laboratory HIV ELISA results in four cases. The DC Ab test failed to detect two HIV-
infected children viz. a 6.9-month old symptomatic infant and a 22.7-month old 
asymptomatic child. Additionally, the DC Ab test failed to detect two 7-month old 
HIV-exposed, uninfected infants possibly because they were in the process of 
seroreverting [46]. 
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Table 2.6: The performance of the HIV Ab component of DC rapid test in HIV-exposed and HIV-unexposed infants. DC diagnosed 
HIV exposure in 64 infants younger than six months of age, of which seven were clinically symptomatic resulting in 100 %sensitivity 
[46]. 
STUDY POPULATION DC HIV ANTIBODY RAPID TEST RESULTS 
HIV-exposed, HIV-exposed, HIV -unexposed, 
uninfected infected uninfected DC Ab+/ Sensitivity % 19501< LR+ DCAb- Specificity % / LR-
Age ELISA+ ELISA- ELISA+ ELISA- ELlSA+ CII ELISA- 195% CII 
~ n PCR- PCR- * PCR+a (%) PCR-
:s 6 79 43 0 21 7 (26.6) 15 64/64 100 [94.3-100] 30.7 15/ 15 100 [79.6-100] 0.00 
>6 - :S18 76 33 31 10 6 (13 .2) 2 40/43 93 .0 [81.4-97 .6] 62 .3 33/33 100 [89.6-100] 0.07 
> 18 47 0 14 30 22 (63 .8) 3 29/30 96.7 [83.3-99.4] 33.8 17117 100 [81.6-100] 0.03 
Total 202 76 45 61 35 (30.2) 20 133/137 97.1 183.3-99.41 65/65 100181.6-1001 
Ab = Antibodies, DC = Detennine Combo, LR = Likelihood Ratio, + = Positive, - = Negative 
Superscript denotes number of symptomatic children (CDC clinic stage Band C), a(%) denotes prevalence; 
*Children in the HIV-exposed, un infected category with negative ELISA results had undergone seroreversion. 
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The DC detected p24 Ag in just one of the 61 HIV-infected infants tested. This three 
month old infant was clinically symptomatic. The sensitivity of DC p24 Ag was 1.7% 
(95% CI 0.3-8.9%). Twelve other HIV-infected infants younger than 18 months were 
clinically symptomatic but none tested p24 Ag positive on DC. This finding suggests 
the hypothesis that DC would be more likely to detect p24 Ag in advanced stages in 
infant HIV infection is not true. 
No false positive p24 Ag results were obtained resulting in 100% (95% CI 97.3-
100%) specificity. 
The LRs were calculated separately for the three age categories (Table 2.6) . The 
formula provided in the methods section would result in an undefined result due to 
the 100% specificity which leads to a denominator of zero for all the age groups. The 
LR values were recalculated by replacing zero as the number of false positive and 
false negative tests by 0.5 to create an understanding of a pretest probability that 
could assist in the assessment and interpretation of the DC test which could be 
useful to clinicians that need to interpret the test. The high positive LR and low 
negative LR demonstrated that the HIV Ab component of DC was reliable for 
exclusion of HIV Ab detection in HIV-exposed or infected infants. 
Twenty seven samples (13%) from the 202 infants tested yielded invalid DC results 
because there was no control band on the DC test strip. These samples were 
retested and valid test results obtained which were used in the analysis. 
2 .3.3 SECTION 3: p24 AG HEAT DENATURATION STUDY 
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The DC test detected HIV Ab in all 15 undiluted samples from HIV-infected mothers 
(n=6) and children (n=9) prior to boiling. The 1:3 diluted heat denatured maternal 
samples yielded 4 invalid tests and two HIV Ab false negative results. Of the five 
heat denatured samples tested in 1:6 sample dilution, two tests were invalid, two 
tests were HIV Ab false negative and only one was HIV Ab positive. Of the nine 
undiluted heat denatured samples from children, six DC tests were invalid and three 
were DC HIV Ab false negative. 
No patient samples tested DC p24 Ag positive, prior to or after heat denaturation. 
The high positive control from the p24 Ag Preci Control kit tested positive on the DC 
p24 Ag strip in the neat and the heat denatured 1:3 and 1:6 diluted samples proving 
the test kit's capability to detect p24 Ag. 
Twenty DC test strips were used with denatured samples of which 12 (60%) were 
invalid. 
Heat denaturation rendered all tests except one either invalid or false negative for 
HIV Ab and did not improve detection of HIV p24 Ag . 
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12.4 DISCUSSION 
2.4 .1 SECTION 1: MATERNAL DC STUDY 
The sample of women enrolled in the study is likely to be representative of the 
population seeking care at RMMCH as 92.7% of women attending antenatal and 
postpartum care over the six month period agreed to participate. The HIV prevalence 
of 17.1 % and 4.6% in women testing antenatally and postpartum respectively is 
similar to a previous description at RMMCH in 2008 [26]. The high HIV prevalence 
rates amongst pregnant women continues to put children at risk of contracting HIV 
infection. 
The fourth generation DC rapid test achieved equal sensitivity in detecting HIV Ab in 
pregnant and postpartum women in comparison to the reference Advanced Quality 
and Acon third generation rapid tests. The specificity of the DC assay in excluding 
the presence of HIV Ab was slightly reduced in whole blood and plasma in 
postpartum women in comparison to women tested antenatally, although still within 
the WHO recommended limits of a specificity of >98% [47]. Two false positive 
results were obtained in the postpartum population. False positive HIV Ab test 
results during pregnancy or shortly thereafter are potentially caused by the cross 
reactivity between HIV Ag and non-specific Ab that are produced by a stimulated 
immune system [48]. In order to maintain diagnostic accuracy and reduce the 
possibility of false positives, it has been recommended that pregnant and postpartum 
women are tested with two rapid tests at the same time (parallel testing) in the field 
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[49] . South Africa presently implements a rapid testing system in which a rapid test 
has to be positive before a second rapid test can be done (serial testing).The DC Ab 
test is sensitive enough for use as an initial screening test but less so as a 
confirmatory second test in the National testing algorithm, because it is less specific 
than currently used third generation tests. 
In this study, DC demonstrated equal sensitivity on whole blood & plasma and all 
the DC test results were valid. A previous study reported that the sensitivity of DC 
was better on serum than on blood and that 16% of DC tests were invalid [5]. The 
difference in outcomes may be accounted for by the presence of EDTA 
anticoagulant in samples from this study which was not present in fingerstick 
samples. In resource limited settings the fingerstick sample collection method is 
more likely to be used for HIV testing in the field and findings in this study may over 
rate DC performance. DC was not assessed on finger stick blood as the study was 
initiated when there was limited literature available on the performance of DC. The 
study took place at a clinical site which routinely uses EDTA blood and plasma for 
rapid HIV testing and was the site that would give DC the best chance for assessing 
performance. It was logistically impractical and unethical to prick the patient twice for 
blood. 
It was found that 2.4% of 505 postpartum women who reported an HIV negative 
status an average of nine weeks prior to repeat testing , had seroconverted within this 
period. This seroconversion rate is less than the 4.5% rate that was described 
previously for this site over a similar time period of five and a half months [26] . 
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Other studies support the finding of incident infections in pregnant and postpartum 
women and draw attention to the problem of newly acquired infections in mothers 
that fuel MTCT in infants [31 , 50-52]. A study of pregnant women in Botswana 
demonstrated that incident cases of maternal HIV infection accounted for 43% of 
infant HIV infection because these women were not identified to receive PMTCT 
[50]. Unless acute infections in women can be detected as part of a PMTCT strategy, 
it may be difficult to attain the global plan that aims for a 90% reduction of new 
childhood infections and a 50% reduction in maternal deaths by the year 2015[2]. An 
improvement in the sensitivity of the DC p24 Ag could aid the detection of early 
maternal HIV infection and thereby potentially curb the spread of HIV from mother to 
child . Laboratory plasma p24Ag testing or DNA PCR or HIV VL testing are used to 
verify recent infection in an ideal world but the costs of these of these tests are 
astronomical for low resource settings. 
The seroconversion rate of 2.4% was an indication that new infections were 
occurring during pregnancy, yet no true positive p24 Ag positive cases were 
detected by the DC test. Aside from the poor sensitivity of the DC p24 Ag 
component, it may be that no women had an acute infection at the time of enrolment 
into this study which may be the reason why not a single true positive p24 Ag 
positive and HIV Ab negative case was found . 
The fa lse positive p24 Ag result found in this study is similar to the findings of a 
Malawian study of DC in which 14 false positive p24 Ag results were obtained 
among 838 HIV-uninfected persons [7] , which infers that the finding of p24 Ag on DC 
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in the field would require confirmatory laboratory testing to ascertain and disclose to 
the patient their true HIV status. 
Furthermore, in a French study of DC in which 200 HIV-infected patients were 
tested, two patients were in the seroconversion phase as confirmed by Western blot 
and laboratory fourth generation ELISA, but were p24 Ag negative on DC [5]. 
Another study reinforces that DC p24 Ag lacks sensitivity as no patients with p24 Ag 
<50pg/ml were detected by DC, and DC detected only 4 out of 9 patients with p24 
Ag between 50-400pg/ml [53]. It was anticipated that DC p24 Ag would have 
reduced sensitivity as compared to laboratory viral detection assays, some of which 
are able to detect p24 Ag levels of 4-5pg/ml [53] considering that rapid tests are 
potentially less sensitive than laboratory based viral detection assays [6, 38]. 
Evidence from these reports reaffirm that the DC p24 Ag component lacks sensitivity 
for diagnosis of acute infection. 
A limitation of this study was that the projected sample size of 200 HIV-infected 
women to be tested was not reached which may have affected the sensitivity and 
95% CI reported here for DC Ab results. However, not reaching the CDC 
recommended sample size of infected women does not affect the evaluation of DC 
p24 Ag sensitivity in diagnosing acute infections, since the population of women 
required to test p24Ag sensitivity is HIV-uninfected women. 
The fact that no new cases were found in the RMMCH population over half a year 
suggests that DC is not useful in our context for identifying acute infections. 
Furthermore, the DC test delivered one false positive p24 Ag and 2 false positive 
HIV Ab results thereby falsely diagnosing new and established infections, which was 
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less accurate than the performance of the third generation rapid tests presently used 
for screening at point of care. 
2.4 .2 SECTION 2: PAEDIATRIC DC STUDY 
Studies have been conducted to determine the most appropriate age at which rapid 
tests can be used to effectively diagnose HIV-exposure and HIV infection in infants 
[44, 54, 55]. Currently available third generation rapid tests are practical for 
diagnosing HIV-exposure in infants younger than 18 months of age and for 
diagnosing HIV-infection in older children. The DC test is the first rapid test that 
broadens the diagnostic spectrum with the potential to diagnose HIV infection in 
children of all ages. 
This is the first study to evaluate a fourth generation rapid test to diagnose HIV 
infection in infants and children. After development DC was evaluated at 9 clinical 
laboratory sites by the manufacturer using commercial seroconversion panels and 
samples from adults. This study was important for assessing the performance of the 
DC test in children , a research priority recommended by the 2008 WHO infant 
diagnosis guidelines [4]. 
Study samples were selected to emulate the clinical scenarios in which infants 
present to healthcare workers at point of care. Irrespective of the clinical status, DC 
would not aid clinicians in the field in diagnosing acute infection in infants and 
children as it failed to detect p24 Ag in 98% of the HIV-infected infants in this study. 
A previous study undertaken in the laboratory on infants aged <3 months and of 
unknown clinical status had similar findings of 1 out of 40 HIV-infected infants testing 
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p24 Ag positive [39]. The poor sensitivity of DC p24 Ag in samples from children is 
comparable to the p24 Ag sensitivity of DC on adult samples [7, 56-58]. 
The DC HIV Ab component is comparable to third generation HIV rapid tests for use 
at point of care to screen for HIV-exposure as the test is 100% sensitive in detecting 
HIV Ab in infants younger than 6 months old. However, the reduced sensitivity of DC 
HIV Ab in infants >6-:::;18 months of age as well at >18 months of age as described in 
our study falls short of the WHO recommended sensitivity of 99% required of rapid 
tests to be used as a screening tool [47]. 
Two H IV-exposed , HIV-uninfected patients who were likely in the process of 
seroreversion contributed to the reduced sensitivity of DC in detecting HIV Ab. The 
two 7 month old infants had detectable maternal HIV Ab on laboratory ELISA tests 
but none on DC. The gold standard HIV PCR result confirmed that the infants were 
HIV-uninfected. 
The DC Ab component failed to identify two HIV-infected infants. The implication of a 
misdiagnosis in the field by a rapid test is that the infants would remain at risk of HIV-
related morbidity and mortality despite having made contact with health care 
services. 
The development of a dipstick p24 Ag assay for earlier detection of infection in 
infants is reportedly 96% (95% CI 88-99) sensitive and 99% specific (95% CI 98-
100) in laboratory evaluations [28]. Prospective improvements to the sensitivity of the 
lateral flow assays and prototype units that aid the heat shocking process at point of 
care [28] could augment early infant diagnosis. 
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Limitations of this study include the small number of children tested in each category 
and the use of samples that were stored for a prolonged period of time. However, 
samples were suitable for this study despite the period of storage as viral p24 Ag is 
reportedly stable in samples stored for 10 years [59]. The study samples appear to 
have undergone no or minimal sample degradation considering that HIV Ab was 
detected in 133 of 137 cases (97%) [46] . 
In this study of stored serum and plasma samples, 13% of DC tests were invalid. 
Other studies reported that invalid DC tests were obtained on finger-stick blood 
without anticoagulant [5, 57], but fewer invalid tests occurred when testing on serum 
[5]. Pavie suggests that the invalid tests are caused by high HIV Ab titres in the 
patient sample which consume the conjugate at the test line in the HIV Ab window 
[5]. The incidence of invalid DC tests in various studies suggests that the DC control 
band needs improvement and that serum should be used to test on DC to minimise 
the number of invalid tests. 
The fourth generation DC test cannot be recommended for a definitive diagnosis of 
HIV- infection in children younger than 18 months. There are more sensitive rapid 
tests to use for detection of HIV-exposure in young infants and for diagnosis of HIV-
infection in older children. 
2.4.3 SECTION 3: p24 Ag HEAT DENATURATION STUDY 
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Boiling of diluted serum and plasma samples releases HIV p24 Ag from the immune 
complex that is formed with HIV Ab and permits the detection of free p24 Ag [15]. 
The DC test was evaluated using heat denatured samples in an exploratory study 
since boiling samples may be possible in some resource limited settings and such a 
method and test could be implemented and useful for the diagnosis of acute 
infection . 
Plasma samples in this study coagulated to an egg white sticky consistency upon 
boiling as was the finding in Schupbach's study [15], making the sample difficult to 
test on the DC strip. Serum samples did not coagulate but had increased viscosity 
post boiling and therefore were not easily absorbed into the DC sample pad . 
The DC HIV Ab component performed inconsistently in the heat denatured samples 
since HIV Ab that was detectable prior to boiling was destroyed in the heating 
process [15], hence the false negative DC HIV Ab results. Even so, in the absence of 
HIV Ab, the p24 Ag remained undetectable on DC. The fact that the DC detected 
p24 Ag in the control p24 Ag sample demonstrates that the DC rapid tests can detect 
p24 Ag but only in high concentrations. The DC p24Ag component of the test 
requires improved sensitivity to detect p24 Ag in the 50 microliters of blood used as 
sample input on the DC strip. 
A limitation to the study was the small number of samples tested. The study was not 
extended to a larger sample set as 60% of DC tests were invalid, signifying that the 
boiling method was not feasible. The heat denaturation method used in our study did 
not increase p24 Ag detection in a rapid test and would not work in resource limited 
settings. A de-tuned ELISA or serological testing algorithm for recent HIV 
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seroconversion (STARHS) has been investigated in Australia for detection of recent 
seroconversion. The test has the potential to detect new infections if it can be 
implemented at point of care. 
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12.5 CONCLUSION 
It is important that rapid H IV tests are evaluated in the laboratory and in the field 
before the tests are recommended for use. In this study, the DC HIV Ab component 
did not perform as well as the two South African Department of Health approved 
third generation rapid HIV tests recommended for use in women and children. The 
DC p24 Ag lacked sensitivity in the field and the laboratory for diagnosing acute HIV 
infection in mothers and definitively determining a positive HIV status in infected 
children less than 18 months of age respectively. The sensitivity of the DC p24 Ag 
could not be improved by a heat dissociation method. 
The fourth generation DC test does not offer an advantage over the currently 
available third generation rapid HIV tests for maternal and child health. 
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CHAPTER 3 
VIRAL LOAD STUDY ON DBS 
13.1 INTRODUCTION 
Substantial progress has been made in managing HIV. Eight million people globally 
and 2.3 million more people in sub-Saharan Africa have gained access to life saving 
ART between 2010 and 2012. South Africa 's scaled up treatment program has 
initiated a further 75% of HIV infected people onto ART over this two year period to 
reach 1.7 million people. [60] . 
The expansion of access to ART requires adequate laboratory infrastructure to 
facilitate HIV VL testing. Quantification of VL is standard of care in the management 
of adult and paediatric populations [61]. VL tests are the WHO preferred test for 
confirmation of an HIV- infected diagnosis in infants that have been identified as 
being HIV-exposed [11], as well as for the monitoring of VL therapy and virological 
failure for those already on treatment [62]. Resource constrained settings face many 
challenges in providing extensive VL testing in spite of bearing the major portion of 
the HIV diseased populations. Some of the challenges of expansion of testing for 
resource limited settings are related to the cost of developing a laboratory testing 
site and the purchase of equipment; the training and availability of qualified 
laboratory staff and the difficulties in accessing technical support for 
troubleshooting[63] . Further challenges in some areas are the lack of physical 
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resources such as electricity, clean water and refrigeration facilities that are 
necessary for storage of samples and reagents. 
Presently, VL testing is conducted predominantly on plasma in South Africa. A VL 
test quantifies the number of HIV RNA copies in 1 ml of plasma [64]. Whole blood 
collected by the phlebotomist needs to be centrifuged so that the separated plasma 
can be tested within 6 hours of sample collection or be refrigerated during 
transportation to the testing site. Rural areas are often less equipped with tools 
required for plasma sample preparation, storage or transportation. Plasma 
Preparation tubes (PPT) are an alternative to EDT A blood collection as they do not 
require plasma separation prior to transportation to the testing site. A disadvantage 
is that the PPT tubes do require cool transportation which is a limitation in resource 
poor settings [47]. DBS have been proposed as a less costly, practical alternative 
sample type to plasma for quantification of VL [8 , 65-69]. Whole blood is spotted on 
to filter paper from a finger or heel prick eliminating the need for skilled venipuncture. 
The filter paper is air dried , stored and transported for testing in a sealed package 
containing a desiccant sachet. Studies have investigated the stability of HIV RNA at 
varying temperatures. One study reported a loss of RNA at 0.026 log copies/ml when 
DBS were stored at room temperature for 7 days [66]. A study of infant samples 
reported a decrease of more than 0.5 log copies/ml in DBS samples stored at 3rC 
for more than 3 months [70]. In contrast, HIV RNA in DBS samples used for infant 
diagnosis and HIV VL monitoring reported that RNA is stable for 10 weeks at room 
temperature [71] . A multicentre study of DBS described that HIV RNA was stable for 
one year in samples stored at room temperature [8] , making DBS the preferred 
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specimen type for rural settings in which challenges such as refrigerated storage 
and cold transportation remain. 
Dried blood spots have been used successfully in resource limited settings for early 
infant diagnosis of HIV [43,70,72] . The 2010 South African National PMTCT 
guidelines [73] recommended that all infants that test positive on the gold standard 
HIV DNA PCR test at 6-weeks weeks of age have a confirmatory VL assay on liquid 
blood at 10-weeks of age even though DBS are much more practical to collect, store 
and transport. Facilities that are able to submit a DBS for the 6 week infant HIV PCR 
screening test often lack phlebotomy skills required to submit liquid blood for the 
confirmatory VL assay [43]. 
Platforms for quantifying VL for monitoring were universally designed to test plasma 
but have been investigated for DBS VL testing [63]. DBS VL testing has been 
studied more extensively in samples from adults [8, 74-76] and in fewer studies on 
samples from children [70-72]. Studies of adult HIV-RNA document high correlation 
between VLs in plasma and DBS samples, [8, 74, 75, 77-80]. Investigations of the 
relationship between samples from children and adults and DBS VL are required to 
elucidate whether DBS VL performs differently in adults as compared to children. 
3.1 .1 VL TECHNOLOGIES 
Viral load technologies from various manufacturers differ in the methods of nucleic 
acid extraction, amplification, detection of the target region using PCR. The PCR 
technique discovered by Kary Mullis in 1983 is a molecular biology method which 
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amplifies DNA into thousands or millions copies of the DNA sequence. [81]. The 
PCR quantitative application of PCR is used to determine VL. The principle of PCR 
is based on a chain reaction in which a DNA molecule is used to produce multiple 
copies of specific proteins known as polymerases (enzyme which binds individual 
DNA into a molecular strand). The PCR process comprises the denaturation, 
annealing and extension stages. In the denaturation step, DNA is denatured at 
temperatures from 90-97 degrees Celsius. Primers anneal to the DNA template 
strand in the annealing phase in which an enzyme "Taq polymerase" synthesizes 
two new strands of DNA at temperatures of 50-60 degrees celcius. In the extension 
phase which takes place at 72 degrees celcius, annealed primers create a 
complementary strand which is an identical copy of the DNA template resulting in 
doubling of DNA quantity through the PCR cycle. A major development of PCR is 
the real time reverse transcription of PCR which enables detection and quantification 
of the products of the PCR process by the use of an oligonucliotide probe which was 
designed to hybridize within the target sequence. The the real time reverse 
transcription of PCR used to determine VL [82] Three such VL technologies are the 
NuciiSens EasyQ-EasyMag HIV-1 assay (bioMerieux,Boxtel, Netherlands) further 
referred to as the EasyQ, Abbott RealTime HIV-1 m2000sp/m2000rt (Abbott 
Molecular Inc, Des Plaines, USA) further referred to as m2000 and COBAS 
AmpliPrep/COBAS TaqMan version 2.0 docked system (Roche Molecular Systems, 
Branchburg, NJ) further referred to as CAP/CTM. 
The EasyQ assay HIV RNA quantification is based on nucleic acid sequence based 
amplification (NASBA) technology. Total nucleic acids are extracted using a method 
so 
described by Boom et al. with amplification that is specific for the gag region of the 
HIV-1 target sequence. The NASBA technique allows for continuous amplification of 
nucleic acids at 41 degrees celcius [83].The m2000 and CAP/CTM platforms utilise 
reverse transcription PCR with real time amplification of the pol and gag regions 
respectively [47]. The m2000 comprises a m2000sp component for RNA extraction 
and m2000rt for amplification and detection. The CAP/CTM is composed of the 
AmpliPrep which performs automated sample extraction and the TaqMan which 
performs the amplification and RNA detection simultaneously ie a real-time assay. 
In September 2010, the EasyQ platform in the South African public healthcare sector 
was replaced by the m2000 and CAP/CTM platforms for routine plasma VL testing. 
The VL measurements on any platform must be precise as decisions regarding ART 
are made according to longitudinal VL measurements and impacts patient 
management. Precision is the degree to which repeated measurements show the 
same result [84], irrespective of the operator, kit lot number, analyser or laboratory 
[85]. Repeated measurements that have the same value are deemed precise but 
may not be accurate [86]. Accuracy is defined as 'the closeness of agreement 
between a test measurement and a true value" [84]. The acceptable precision limits 
for VL in plasma is a coefficient of variation (CV) of <35% on the untransformed 
copies/ml value and a standard deviation (SO) of :S;0.19 copies/ml on the log 
transformed VL value as reported by the international Viral Quality Assurance (VQA) 
programme (Rush Presbyterian- St Luke's Medical Center, Chicago, IL) and two 
other studies [87, 88]. The SO and CV precision limits for OBS samples are not well 
documented. 
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Although VL testing on DBS is not yet approved for diagnostic use by the 
manufacturers of m2000 and CAP/CTM, studies to provide data on DBS VL testing 
are necessary in order to improve HIV testing programs in resource limited settings 
[77]. Presently, plasma VL results are utilised by clinicians to ascertain the baseline 
HIV RNA copies/ml prior to initiation of ART and determine the need to change 
therapy [89]. Baseline VL are expected to be high. As treatment progresses VL 
results are expected to reduce and therefore are markers of successful therapy [14]. 
An increase in 110g copies/ml VL is clinically relevant to alert the need for follow up 
and decision to switch therapy[62] The aim of ART is to maintain a VL below the 
lower limit of detection of the testing platform [90]. The lower limit of detection also 
known as a threshold is the point at which the minimal number of false positive 
results occur [91]. The DBS VL lower limit of detection varies according to the 
platform used and various VL lower limits of detection for DBS have been reported 
for the same platform [91]. 
A study conducted in Cameroon reports a 3 log copies/ml threshold using the m2000 
platform [79] in comparison to the 3.72 log copies/ml threshold reported by Garrido 
et al. [76] on the m2000 and EasyQ platforms on DBS. The difference in the DBS 
VL threshold between 3.0 and 3.7 log copies/ml represents changes in VL copies of 
1000 to 5000 copies/ml [91]. The 2013 WHO guidelines and South African treatment 
guidelines on the use of ART describe an increase in plasma VL of >1000 copies/ml 
(change of 310g copies/ml) over two consecutive measurements two months apart as 
virological failure [62, 89] in patients that had previous undetectable VL. The 
guidelines recommend a higher threshold at 3000-5000 copies/ml (3.5 - 3.7 log 
copies/ml) when testing on DBS [62]. For clinical decision making, one needs to be 
able to translate a DBS VL into a plasma VL along the continuum of care. Therefore 
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the relationship between DBS and plasma VL measurements need to be further 
elucidated in the South African setting if DBS are to be used for HIV-monitoring 
purposes in the future. The DBS VL limits of detection and VL precision are issues 
that remain poorly described [91]. 
Data on the specificity of DBS VL on m2000 and CAP/CTM would allow for an 
evidence-based decision on whether DBS could be substituted for plasma samples 
in VL testing for confirmation of a positive HIV infection status without using a 
threshold . The implication of a high specificity is that the platforms are accurate and 
could therefore potentially be utilised to diagnose HIV-infection. 
A study of the EasyQ assay as a modality for early infant diagnosis in a South 
African subtype C population yielded 6/157 (3.8%) false positives and 96.2% 
specificity in DBS samples from infants younger than three months of age [72]. The 
study demonstrated that using a threshold of >4 log (10000 copies/ml) to diagnose 
HIV infection minimized the number of false positive results. The danger of a low 
false positive confirmatory VL result is that an HIV-uninfected infant could be 
erroneously commenced on life-long ART [72] . However, if the specificity of the 
m2000 and CAP/CTM VL assays on DBS exceed 98%, [11] then the platforms 
could be used with confidence by clinicians for diagnosis. A high specificity reaffirms 
that the assays are HIV RNA specific and therefore would not detect VL in HIV-
uninfected persons [85] . 
A potential complication for using a DBS sample for the m2000 assay is that the 
work done to date has required the use of two spots (±100ul) per DBS card [75, 77-
79] . In routine practice, only three spots per DBS card are generally collected from 
infants leaving too little sample should a second VL test be required e.g. in the event 
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of failure of test controls where the test sample would need to be retested. In this 
study, the m2000 platform was also assessed on one spot (± 50ul) with a view to 
enabling easier implementation of DBS testing. 
The aim of this study was to evaluate the performance characteristics of DBS VL 
testing on the CAP/CTM and m2000 technologies to assess whether DBS can be 
used to confirm a diagnosis of HIV-infection and for VL monitoring. Due to the 
scarcity of infant blood samples with sufficient volumes for routine and research 
testing, adult samples were included in the study. The findings would establish 
whether adult DBS VL results could be generalised to children using the platforms 
currently in use in South Africa. 
The objectives were to assess DBS VL by: 
1) Establishing DBS VL accuracy 
• By comparing the VL results of HIV-infected children and adults 
obtained on DBS and plasma (gold standard) on the CAP/CTM and 
m2000 platforms 
• By ascertaining the specificity of DBS VL on the CAP/CTM and m2000 
platforms using DBS from H IV-exposed , uninfected infants 
2) Establishing DBS precision limits 
• intra-assay precision (repeatability) by replicate testing of DBS VL on 
the same sample by a single operator, on the same day, using the 
same reagents and equipment. 
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• inter-assay precision (reproducibility) of DBS VL which measures 
whether the test result of the same sample, could be replicated by 
another operator at different time points. 
3) Establishing the accuracy and precision of the m2000 using 1 DBS spot 
versus 2 DBS spots. 
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13.2 MATERIALS AND METHODS 
3.2.1 STUDY LAYOUT AND SAMPLES 
A prospective study of DBS VL accuracy and precision limit on the CAP/CTM and 
m2000 platforms were conducted on 10 adult and 10 children per platform (Figure 
3.1) . DBS were made from EDTA blood collected from HIV-infected adults attending 
a wellness clinic, whereas DBS from children were made from EDTA samples 
submitted to Charlotte Maxeke Johannesburg Academic Hospital's (CMJAH) PCR 
lab for VL testing . Plasma derived from the EDTA blood was tested for VL on both 
platforms. The plasma VL result was the gold standard used to assign patient DBS 
samples into five stratified VL categories namely, undetectable, low (S3 log), medium 
(>310g and S4 log), high (>410g and S5 log) and >5 log. Two patients were tested in 
each VL category (Figure 3.1). Furthermore, plasma VL in the undetectable category 
included samples in which the target was not detected and reflected as a zero 
plasma VL. Plasma samples and DBS with RNA below the detectable limit of 20 
copies/ml on CAP/CTM and below 40 copies/ml on m2000 were reflected as having 
19 copies/ml (1.3 log) for both platforms. 
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Viral load study on Dried Blood Spots 
Objective 1: 
Accuracy 
1. DBS VL VS. Plasma VL 
n=10Adult plasma; 10 OBS/per patient 
n= 10 Paediatric plasma; 5 OBS/patient 
2. SPECIFICITY 
200 paediatric patients (4 OBS/patient; 8000BS) 
Objective 2: 
Precision limits 
1. HIV- infected plasma and DBS 
Plasma VL was used to assign OBS into 5 VL categories: 
undetectable. low«310g). medium(>3 log <4 log), high(>4 
log<5 log) and >5 log. 
Two patients (5 or 10 replicates per patient) were tested in 
each category. 
/~ 
Adult: n=20 II Children: n=20 
Intra and Inter variability Intra variability 
at) I I CAP/CTM (1 sp 
I m2000 (1 spot) 
( 
Objective 3: ( 
1 spot vs. 2 spot I m2000 (2 spots) 
I 
Figure 3.1: A flow diagram that describes the objectives and number of samples 
tested in the accuracy and precision study of DBS VL on the CAP/CTM and m2000 
platforms. 
The accuracy study assessed in five viral load categories, the difference between a 
single gold standard plasma VL result and multiple DBS VL results. Ten DBS VL 
results were obtained per adult and five DBS V results per child. 
The study of DBS VL accuracy was extended to a study of specificity in which 800 
stored DBS samples from 200 HIV-uninfected infants were used to ascertain the 
false positive rate on CAP/CTM and m2000 platforms. Two hundred VL tests were 
utilised to test 200 single DBS samples on CAP/CTM. Six hundred DBS were tested 
on the m2000 such that 200 DBS were tested in the one spot assay (using 200 tests) 
and 400 DBS were tested in the 2 spot assay (using 200 tests). In total, six hundred 
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assay tests were utilised to test 800 DBS between the two platforms to assess 
specificity (Figure 3.1). 
The qualitative result (e.g. detectable or undetectable) from the DBS VL assays were 
compared to the gold standard negative HIV DNA PCR result. 
The DBS VL precision study was conducted to establish the precision limits (SO and 
CV) of DBS on the CAP/CTM and m2000 platforms. Inter-assay and intra-assay 
precision studies were conducted on adult DBS, however only intra-assay precision 
was evaluated on DBS collected from children due to the limited amount of blood 
available from children (Figure 3.1). 
No direct comparison of the VL data was made as the patients tested on the 
CAP/CTM platform were not the same patients that were tested on the m2000 
platform. 
Ethics approval (M091133) to conduct VL studies on adult and paediatric populations 
was granted by the Human Research Ethics Committee at the University of the 
Witwatersrand , Johannesburg (Appendix A). 
3.2.1.1 OBS SAMPLE PREPARA TION - AOUL TS 
Patients at the Helen Joseph hospital's Themba Lethu clinic were invited to 
participate in the study if they were HIV-infected, irrespective of their ART history, if 
58 
they were older than 18 years of age. Informed consent was obtained, one 5ml tube 
of EDTA blood was drawn, labelled with a study number without patient identifying 
details, packaged and transported to Charlotte Maxeke Johannesburg Academic 
Hospital (CMJAH) within 6 hours of collection for DBS VL sample preparation and 
gold standard plasma VL testing. At CMJAH, Whatman 903 filter paper cards (GE 
Healthcare Bio-Sciences Corp. Westborough, MA, USA), each containing five pre-
printed circles were labelled with a study number. The EDT A samples were mixed by 
gentle inversion before the DBS cards were spotted under a laminar flow unit. For 
the CAP/CTM platform, ten spots (2 cards) were prepared consisting of 751..11 whole 
blood per spot (as per manufacturer suggestions). DBS for the m2000 were 
prepared by ten spots (2 cards) containing 501..11 were made for the 1 spot evaluation. 
An additional twenty spots (4 cards) of 501..11 blood were made for the m2000 2 spot 
assessment (as per manufacturer suggestions). 
The DBS cards were labelled and left to dry at ambient temperature (20°C) in drying 
racks for a minimum of three hours before packaging individually into plastic zip-lock 
bags with desiccant sachets and stored at room temperature (20-25°C) . 
The remaining EDTA blood was centrifuged and 1 ml plasma aliquots were labelled 
and stored at -70 c C until sufficient samples had been collected to commence batch 
testing . Plasma aliquots were subsequently defrosted at room temperature and 
tested on CAP/CTM using the COBAS Ampliprep/COBAS CAP/CTM HIV-1 test, 
version 2.0 kit (Roche Molecular Systems, Inc., Branchburg, NJ, USA). Plasma 
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reference standard VL on the m2000 was obtained using the Abbott RealTime HIV-1 
kit (Abbott Molecular Inc. , Des Plaines, IL,USA). 
3.2.1.2 DBS SAMPLE PREPARA TlON - CHILDREN 
Whole blood EDTA-anticoagulated samples submitted for routine HIV VL testing at 
the PCR laboratory at CMJAH were intercepted at the sample receiving office and 
screened using the laboratory information system. Patients whose ages ranged from 
birth to 15 years and were identified to be HIV-infected using their previous VL 
records were selected for the DBS VL study. Blood from identified HIV-infected 
patients were anticipated to contain undetectable or low VL if the patients had 
accessed ART, but no clinical data was available on any of the patients to verify their 
ART status. Samples from paediatric patients that had no previous record of VL 
testing were also included as they were anticipated to have high VLs assuming that 
these were baseline VL samples submitted prior to the initiation of ART. DBS and 
whole blood for the study were prepared only if a minimum of 3ml EDT A blood had 
been submitted by the clinician so as not to compromise the sample volume required 
for routine testing. 
For the study, one DBS card (consisting of 5 x 501-11 spots) per patient was made, 
and an aliquot of 12001-11 of whole blood was separated from the EDTA sample 
before the routine testing was performed. The DBS were packaged and stored with a 
desiccant sachet at room temperature after drying overnight.. The 12001-11 EDTA 
blood was centrifuged to obtain plasma which was stored at -70°C. Plasma samples 
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were thawed in batches of 24 samples and tested either on the m2000 or CAP/CTM. 
The plasma VL results from each platform were used to assign DBS samples to that 
platform in the five VL categories. DBS were used to test intra-precision exclusively 
as the number of DBS that could be made were limited by sample volume and 
adequate samples could not be made from samples from children to incorporate 
inter-precision testing. The CAP/CTM and m2000 intra-precision was assessed on 
one 50ul spot in replicates of 5 per patient. 
3.2.2 ACCURACY TESTING : STUDY DESIGN 
The accuracy of DBS VL was measured in two ways: 
Firstly, by comparing gold standard plasma VL to 10 DBS VL replicates for each of 
the two patients tested in the 5 VL categories. In paediatric patients, each plasma VL 
was paired to 5 replicate DBS VL. 
Secondly, specificity was also measured. Stored DBS samples were sourced from a 
2010 study in which DBS samples were prospectively collected from a well 
characterized cohort of 6-week old infants of known H IV-exposed , uninfected status, 
as determined by an HIV DNA PCR test [92]. DBS cards that had four filled spots per 
patient were selected to ensure that the same patient could be tested on both the 
CAP/CTM (using 1 spot) and m2000 platforms (1 spot and 2 spot) 
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3.2.2.1 CAP/CTM DBS VL ACCURACY TESTING 
One DBS was excised under a safety hood using scissors that were swabbed with 
2% bleach and 70 % ethanol and dried between samples. The spot was placed into 
the conical part of the sample processing unit using sterile forceps, and eluted for 10 
minutes at 56°C during continuous shaking in 1 ml of pre-extraction lysis reagent per 
the manufacturer's instructions. The sample pre-extraction procedure allowed for 
nucleic acid release from the white blood cells and stabilised the nucleic acids 
against enzyme degradation. The samples were subsequently loaded onto the 
AmpliPrep analyser in batches of 24 samples (21 samples and 3 controls). The 
COBAS AmpliPrep/COBAS TaqMan HIV-1 test, version 2.0 kit (Roche Molecular 
systems, Inc. , Branchburg , NJ 08876 USA) and the COBAS Ampliprep/COBAS 
TaqMan HIV-1 test Dried Fluid spot protocol (HI2DFS96) was used for the HIV RNA 
extraction and detection for plasma and DBS respectively. 
The CAP/CTM instrument used in this study was a docked system, with no need to 
manually transfer the test reaction from the AmpliPrep to the TaqMan as the system 
was fully automated after samples were loaded. 
HIV-infected high positive, low positive and HIV-uninfected plasma quality controls 
as supplied in the test kits were included in every run on both platforms and the DBS 
VL results were only considered valid if all three control results were within the range 
specified by the manufacturer. 
The DBS samples from children were processed and tested in the same way as the 
adult DBS samples on the CAP/CTM. 
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The CAP/CTM has a reportable range of 20 to 1.0E+ 7 HIV RNA copies/ml [93] 
3.2.2.2 m2000 DBS VL ACCURACY TESTING 
One 50ul spot for the adult intra- and inter-precision study and for the child intra-
precision study was excised using a 12mm hand held punch. The punch was 
cleaned between patient samples by punching five spots from blank Whatman 903 
DBS card using a method described by Driver [94]. Similarly, two DBS were cut for 
the comparison study of 1 spot VL versus 2 spot VL. 
The DBS were placed in 50ml sterile conical shaped tubes to which 1.7ml sample 
preparation buffer was added and eluted after 20 minutes. The lysis buffer aided in 
the release of nucleic acid from the white blood cells. The 1.7mllysate, excluding the 
DBS, was pipetted to 5ml reaction vessels and loaded onto the m2000sp system for 
RNA extraction. An internal control which reinforced non-inhibition of the real time 
PCR reaction was included in every sample tested. Additionally, three levels of 
plasma controls as supplied by the manufacturer, were included in every batch of 
testing . Study results were considered to be valid only if the controls were within 
range as described by the manufacturer. 
The DBS VL were tested on the Open mode 1ml DBS HIV-1 RNA protocol 
application for 90 minutes. Post the 90 minute RNA extraction, a reaction plate 
containing HIV RNA eluate was manually transferred to the m2000rt for RNA 
amplification and detection. The m2000 assays detects VL in the range of 40 to 
1.0E+ 7 HIV RNA copies/ml [95]. 
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3.2 .3 PRECISION TESTING : STUDY DESIGN : 
3.2.3.1 CAP/CTM OBS VL PRECISION TESTING 
The precision testing on samples from adults and children on the CAP/CTM platform 
was performed by a single operator on a sole analyser designated to this study in a 
high throughput laboratory. Intra-assay precision (repeatability) was measured by 
replicate testing of five DBS samples from each patient on the same day, within a 
single run using the same reagents and equipment. The inter-assay precision 
(reproducibility) was tested to evaluate if the DBS VL results could be replicated in 
separate test batches over five days. DBS samples were processed and were the 
same samples as described in the accuracy study in section 3.2.2.1 
3.2.3.2 m2000 OBS VL PRECISION TESTING 
The intra and inter precision limits of DBS from adults and children on the m2000 
platform took place using the processes described for the CAP/CTM in section 
3.2.3.1 . The study of DBS VL accuracy and precision limits were conducted on the 
same sample set and were processed as described in section 3.2.2.2. 
3.2.4 STATISTICAL ANALYSIS 
Accuracy study: Bland Altman statistical plots [96] were used to assess the 
agreement between gold standard plasma VL results and the DBS VL method on log 
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transformed VL results. The difference between plasma and OBS VL was plotted on 
the Y-axis. The log values of gold standard plasma viral load (not the average 
between plasma and OBS as shown in conventional Bland Altman plots) were 
presented on the X-axis on the CAP/CTM and m2000 plots. 
The bias was calculated as the mean paired difference between plasma and OBS 
VL. SO of the bias was a measure of the spread of values and was calculated by the 
square root of the variance. Variance was the average of the squared difference 
from the mean (average), and was calculated by ascertaining the mean of the data 
set. The mean was subtracted from each data point and the difference was squared. 
The CV was calculated as a percentage from the ratio of the SO to the mean and 
was a measure of the variability and stability of data. Adult and child populations for 
each platform were plotted separately. 
The upper limit and lower limits of agreement were calculated as SO±1.96 multiplied 
by the mean to show the overall difference for 95% of the data. The distance over 
the limits of agreement was calculated as the difference between the upper and 
lower limits of agreement. The percentage of outliers represented the OBS VL 
measurements that were outside the limits of agreement [97]. The number and 
percentage of RNA copies/ml outliers for >0.5 log copies/ml, >1 .0 log copies/ml, 
>210g copies/ml and >310g copies/ml were reported to ascertain the extent of the 
difference between OBS and plasma VL in each of the 5 VL categories. 
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The percentage similarity plots [97] were created to measure the agreement 
between plasma and OBS VL. To calculate percentage similarity the average 
between the gold standard plasma VL and OBS VL (both log copies/ml) was divided 
by gold standard plasma VL results and represented as a percentage of the gold 
standard. The comparison was visualised though a 100% similarity reference that is 
common to the m2000 and CAP/CTM plots [97] . The formula [({a+b}/2)/a] x 100 was 
used , where "a" was the reference plasma VL and "b" was the test method of OBS 
VL [97]. The mean percentage similarity values between plasma and OBS VL were 
calculated to be 100% if the VL in the two methods were the same. When OBS VL 
results were higher than plasma VL results, the mean percentage similarity was 
calculated as being greater than 100%. The converse of OBS VL being lower than 
plasma VL resulted in mean percentage similarity value calculation of less than 
100%. 
The specificity (true negatives / (true negatives+ false positive), of the CAP/CTM and 
m2000 (1 and 2 spot) assays was calculated using HIV-ONA PCR results as the 
reference standard. 
Study of precision limits: The OBS intra- and inter- assay precision limits were 
assessed by calculating the SO on log transformed VL values and the CV on the 
absolute VL values for the five VL categories. The SO and CV values were 
calculated as described in the accuracy study. Plasma VL results were the reference 
standard for intra- and inter- assay precision measurements. An SO value of $0.19 
log copies/ml and a CV of $35% was considered acceptable [88]. The total assay SO 
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on intra- and inter-assay precision was calculated on adult samples using the 
formula: Total assay SO = J (intra SD) 2 + (inter SD) 2. 
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13.3 RESULTS 
3.3 .1 SAMPLE YIELD 
DBS were stored at room temperature (20-25 degrees Celsius) for a six month 
period from sample collection to testing . Of the 400 prospectively made DBS from 
adults and children, 150 DBS spots were tested on CAP/CTM and 250 DBS on the 
m2000 platform. The CAP/CTM and m2000 assays yielded 149 (99.3%) and 195 
(78%) valid resu lts respectively. Of the 100 tests performed on 1 and 2 spot DBS 
from adults, 75(75%) and 77 (77%) valid results were obtained respectively. Several 
automation and technical errors were encountered, using the m2000 assay and are 
described in Table 3.1. The majority of errors on the m2000 assay occurred in adult 
samples as compared to paediatric samples. 
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Table 3.1: Number of valid tests and errors obtained on the DBS precision tests 
performed on the m2000 and CAP/CTM platforms. 
m2000 assay CAP/CTM assay 
n error adult child adult child 
code 
1 SPOlt 2 spot 1 spot 1 spot 1 spot 
n tests 100 100 50 100 50 
valid results 84 83 43 100 49 
errors ""invalid 0 0 0 0 1 
3118 B 3 0 0 0 
4442 10 14 3 0 0 
3131 0 0 2 0 0 
4457 0 0 2 0 0 
*invalid : sample failed ; 3118: Clot limit passed error, 4442: internal control cycle number too high; 
3131 : more liquid than expected error; 4457: internal control failure 
3.3.2 ACCURACY STUDY: 
The Bland-Altman plots (Figures 3.2; 3.3; 3.5-3.7) represent the difference in VL 
between plasma and DBS in samples from children and adults. 
3.3.2.1 CAP/CTM DBS VL 
The CAP/CTM generates 3 types of VL results, namely 'target not detected'; 'target 
detected but not quantifiable' and 'target detected and quantifiable'. In this study of 
the CAP/CTM, 'target not detected' VL results obtained on plasma and DBS samples 
are reflected on the Bland-Altman plot as zero VL (Figure 3.3A) and in Figure 3.4 
which compares DBS VL to plasma VL. 
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The lower limit of RNA detection on the CAP/CTM is ~20 copies/ml and is resulted 
as ' target detected but not quantifiable'. Such DBS and plasma VL results were 
reflected on the Bland-Altman plot as 1.3 log copies/ml (19 copies/ml) (Figure 3.2A). 
In both adult and paediatric samples, DBS VL was detectable and quantifiable where 
plasma VL was undetectable. DBS VL values were higher than plasma VL by 2 log 
copies/ml in 90% (9/10) of samples from children and by 3 log copies/ml in 70% 
(14/20) of adult samples. Additionally, DBS VL values were higher than plasma VL 
by >2 log copies/ml in the lower range «310g, 1000 copies/ml) and lower than 
plasma VL values by <0.5 log copies/ml in the higher range (>510g, ~185 OOOc/ml) 
(Figure 3.2 A and 3.3 A) . DBS and plasma VL showed the least differences in 
percentage similarity closest to 100% at VL>410g copies/ml (Figure 3.2 Band 3.3 B). 
Differences and outliers of >1000 copies/ml-between plasma and DBS VL occurred 
between plasma VL undetectable samples to plasma VL's of 410g (10 000 
copies/ml) (Table 3.2). The difference of >1000 copies/ml is clinically significant in 
patients that previously had undetectable VL. Compared to plasma VL, DBS VL 
values were >0.510g higher in 53% (26/49) of specimens. Of these outliers, 16 DBS 
VL measurements had a difference of >1 .010g in children (Table 3.2). Similarly in 
adults, DBS VL results were 0.5 log higher than plasma VL in 59% of (59/100) 
observations. The outliers included 42 DBS VL in which a difference of >110g was 
reported (Table 3.2) . Differences of >2 log between plasma and DBS VL were 
obtained in 18% and 31% of child and adult DBS VL measurements respectively 
(Table 3.2) in the plasma VL <310g category (Figure 3.2 and 3.3) . The scale on x-
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axis of figure 3.2B and the subsequent plots represents the plasma VL from the ten 
patients tested. 
Bias values close to zero were interpreted as favourable and a zero difference 
implied equality between the two methods [97]. In children , the bias of plasma and 
OBS VL measurements was closer to zero at >410gs and at >510gs in adults. The 
bias and disparity between plasma and OBS VL methods was largest at <310gs 
(Table 3.2). 
The variability in the differences between plasma and OBS VL measurements was 
assessed by calculating the SO of the differences. The lower the SO of the 
differences, the lower the variance. High CV values were associated with the greater 
variability. 
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Figure 3.2: CAP/CTM on samples from children. A: Bland- Altman plot showing that 
the differences between plasma and DBS VL were larger at lower range of plasma 
viral loads platform. VL was detectable in DBS even where plasma VL was 
undetectable. B: DBS VL were similar to plasma VL at plasma VL measurements 
>410g. 
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plasma viral loads. VL was detectable in DBS even where plasma VL was 
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Table 3.2: Bland-Atman and percent similarity statistical parameters for measuring DBS VL accuracy in adults and children on the 
CAP/CTM platform. 
CAP/CTM: Bland-Altman Parameters % Similarity 
No. ('!'o) of outliers 
SD of 
Bias difference Distance over >Iog 0.5 log >Iog 1 log >Iog 210g >Iog 310g Mean SD %CV 
(log RNA (log RNA Limits of limits (log RNA RNA RNA RNA RNA 
Comparison VL categories copies/ml) copies/ml) agreement copies/ml) copies/ml copies/ml copies/ml copies/ml 
undetectable -2.25 0.15 -4.26; 4.57 -8.83 10/10 (100) 10/10 (100) 9/10(90) 0110 (0) 193.90 6.40 3.30 
~310g -0.98 0.22 -1.70; 2.13 -3.82 10/10 (100) 6/10 (60) 0/10 (0) 0/10(0) 120.09 4.95 4.12 
Plasma 
>3 - S410g -0.52 0.41 -0.60; 1.43 -2.03 6/10 (60) 0/10(0) 0/10 (0) 0/10(0) 107.63 6.03 5.60 
vs 
>4 - ~510g -0.03 0.14 0.08; 0.19 -0.11 0/10(0) 0/10(0) 0/10 (0) 0/10(0) 100.28 1.60 1.59 DBS 
(children) >5 log -0.02 0.27 11 .25; -1072 21 .97 0/9 (0) 0/9 (0) 0/9 (0) 0/9 (0) 100.12 2.41 2.40 
summary -0.77 0.87 0.94; -2.49 3.42 26/49(53) 16/49 (33) 9/49 (1 B) 0/49(0) 124.90 36.34 29.10 
undetectable -3.46 0.52 -6.26; 7.31 -13.57 20/20 (100) 20/20 (100) 20/20 (100) 14/20 (70) "15640.30 5319.31 34.01 
~310g -2.17 0.41 -3.83; 4.66 -8.50 20/20 (100) 20/20 (100) 11 /20 (55) 1120 (5) 163.30 17.15 10.50 
Plasma 
>3 - $4 log -0.66 0.26 -1.02; 1.55 -2.58 15/20 (75) 2120 (10) 0/20 (0) 0/20 (0) 109.91 4.28 3.89 
vs 
>4 - $5 log -0.28 0.25 -0.30; 0.79 -1.09 4/20 (20) 0/20 (0) 0/20 (0) 0/20 (0) 103.21 2.85 2.76 DBS 
(adult) >5 log 0.04 0.21 0.30; 0.12 0.17 0/20 (0) 0/20 (0) 0/20 (0) 0/20 (0) 99.62 1.98 1.99 
summary -1 .30 1.37 1.38; -3.99 5.37 59/100 (59) 4211'00 (42) 31 /100 (31) 15/100(15) 119.01 27.46 23.07 
"Mean percentag.e si milarity is raised due to the presence of provira l DNA 
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3.3.2.2 m2000 DBS VL 
Plasma VL measurements in which RNA was undetectable were matched by 
undetectable DBS VL demonstrating 100% mean percentage similarity between 
DBS and plasma in samples from children (Figure 3.5B) and adults (Figure 3.6B and 
3.7B). VL was undetected in 39 DBS samples (n=9 paediatric and n=30 adult) of 
which VL was detectable in the corresponding plasma samples (Figure 3.5- 3.7) and 
9) . The false negative measurements appear as outliers on the points plot that depict 
differences of up to 4 log copies/ml between plasma and DBS VL (Figure 3.5A, 3.6A 
and 3.7A). DBS VL were not detected in samples below 4.5 log copies/ml resulting in 
the lowest mean percentage similarity for m2000 of 87.35% in children and 77.38% 
in adu lts (Table 3.3) . 
Compared to plasma viral loads DBS VL results were: 
1) >0.510g higher in 49% (21/43) and >1.010g higher in 16% (7/43) of DBS 
replicates from children (Table 3.3) . 
2) >0.510g higher in 61 % (51/83) and >1.010g higher in 22% (18/83) adult 1 spot 
DBS VL measurements (Table 3.3). 
3) >0.510g higher in 39% (32/82) and >1 .0I0g higher in 24% (20/82) adult 2 spot 
replicates (Table 3.3) 
Overall, the DBS VL bias was greatest between 3-410g copies/ml in samples from 
adults and children. 
DBS VL at >310g demonstrated higher VL from 2 spots as compared to one DBS 
spot (Figure 3.8) . 
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Table 3.3 : Bland-Atman and percent similarity statistical parameters for measuring DBS VL accuracy in adults and children on the 
m2000 platform. 
m2000: Bland-Altman Parameters % S imila rity 
No.(%l of outli ers 
Distance 
Bias SO of d ifference over limits >109 0.5 >1091 log >Iog 2 10g >Iog 3 109 Mean SO %CV 
VL (log RNA (log RNA Limits of (log RNA log RNA RNA RNA RNA 
Compari son categories copies/ml) copies/ml) agreement copies/ml) copies/ml copies/ml copies/ml copieslml 
undetectable 0.00 0.00 0.0; 0.0 0.00 0/9 (0) 0/9 (0) 0/9 (0) 0/9 (0) 100.00 0.00 0.00 
5:3 log -0 .14 1.09 0.81; U 7 -0 .55 10/10 (100) 4/10 (40) 0/10 (0) 0/10 (0) 103.19 27.02 26 .18 
>3 - 5:4 log 0.25 0.73 1.22; 0.24 0.98 1/10(10) 1/10 (10) 1/10 (10) 0/10 (0) 96.49 10.40 10.77 
P lasma lIS DBS >4 _ 5:5 10 1 08 1.08 3.21; -1.04 4.25 6/9 (66) 219 (22) 219 (22) 0/9 (0) 87.35 12.91 14.79 (children) 5 I 9 
> og 0.57 0.09 1.22; -1.03 2.24 4./5 (80) 0/5 (0) 0/5 (0) 0/5 to) 95.11 0.80 0.84 
s ummary 0.32 0.89 1.52; 0.27 1.25 21/43 (49) 7/43 (16) 3/43 (1) 0/43 (0) 96.43 15.58 16.11 
undetectable 0.00 0.00 0.00 ; -0.00 0.00 0/17 (0) 0/17 (0) 0117 (0) 0/17 (0) 100.00 0.00 0.00 
5:3 log 1.02 1.53 3.53 ; -0.48 4 .01 17117 (100) 10/17 (59) 10/17 (59) 0/17 (0) 77.38 33.78 43.65 
>3 - 5:4 log 1.49 1.45 4 .37; -1.47 5.84 10/16 (63) 5/17 (29) 5/17 (29) 5/17 (29) 79.23 20 A1 25.75 
Plasma lIS DBS >4 . 5:5 10 0.54 0.44 1.50; -0.62 2.13 9/17 (53) 2117 (12) 0/17 (0) 0117 (0) 94.01 4.84 5.15 (adult) 1 spot 5 1 9 
> og 0.76 0.41 1.90; -1.07 2.97 15/16 (94) 1/16 (6) 1/16 (6) 0116 (0) 93.02 4.09 4.39 
summary 0.75 1.07 2.55 ; -D AD 2.96 51/83 (61) 18/83 (22) 16/83 (19) 5/83(6) 85.90 21.12 24.59 
undetectable 0.00 0.00 0.00; 0.00 0.00 0/15 (0) 0/15 (0) 0/15 (0) 0/ 15 (0) 100.00 0.00 0.00 
5:3 log 0.80 1.68 3.24; 0.11 3.13 18/18 (100) 15/18 (83) 10/ 18(56) 0118 (0) 82.21 37.16 45.19 
>3 - 5:4 log 1.08 1.48 3.61; -0 .64- 4.25 6117 (35) 4/17 (24) 4/17 (24) 411 7 (24) 85.09 20 .25 23.80 
P lasma lIS DBS >4 _ 5:5 10 0.36 1.14 1.86; 0.43 1.43 2116 (13) 1/16 (6) 1/16 (6) 1/16 (6) 95.96 12.72 13.25 (adult) 2 s pots 5 I 9 
> og 0.44 0.15 1.01; -0 .72 1.73 6/16 (38) 0/16 (0) 0/16 (0) 0/16 (0) 96.06 U 1 U6 
s ummary 0.56 1.19 228; 0.09 2.19 32182 (39) 20/82 (24) 15/82 (18) 5/82 (6l 89.53 23.07 25.77 
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Specificity 
Of the 600 DBS from HIV-uninfected 6 week old infants tested on the m2000 platform, 315 (78.7%) samples were valid. Errors 
occurred in the one and two spots runs and are described in Table 3.4. The specificity of the m2000 assay was 100% (95% CI 
98.8-100). 
The CAP/CTM yielded 100% results from the 200 DBS tested from HIV-uninfected 6 week old infants as no errors and no false 
positive results were incurred. The specificity of the CAP/CTM assay was also 100% (95% CI 98.1-100) 
Table 3.4 : Specificity of the CAP/CTM and m2000 assays. The m2000 produced fewer valid results. 
Platform 
m2000 
CAP/CTM 
1 spot 
200 
200 
Tests 
2 spot 
200 
total tests 
analysed 
400 
200 
*errors occurred in one and two spot DBS sample 
n DBS 
tested 
600 
200 
n valid results 
*315 (78.7%) 
200 (100%) 
Results 
n false 
positives 
o 
o 
specificity 
100%(98.8-100%) 
100%(98.1-100%) 
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3.3.3 PRECISION STUDY 
3.3.3.1 CAP/CTM DBS VL PRECISION 
For CAP/CTM, the intra-variability was less variable than the inter-variability in 
adults. Using plasma precision limits (SO= <0.1910g copies/ml) as the acceptable 
limit, (the total SO was acceptable in 5/10 (50%) of adult patients across the 5 VL 
categories. The total SO could not be calculated for the samples from children as the 
calculation required inter-precision as well as intra-precision measurements. OBS 
from children were only tested for intra precision and the SO obtained was 
acceptable in 8/10 (80%) of children across the 5 VL categories (Table 3.5). 
The acceptable %CV limit for plasma precision is <35%. High %CV values were 
observed in samples from adults and children in all VL categories with the exception 
of the 2:510g copies/ml VL category (Table 3.5 and 3.6). The inter-precision %CV 
values that were >35% ranged from 36.80% to 117.72% in adults (Table 3.5) . In 
children , only intra-precision was measured and the %CV values >35% ranged from 
39.77% to 77.84% (Table 3.6) .Of the 10 adult and 10 children tested for intra-
precision, 90% of adult samples and 60% of samples from children met the 
acceptable plasma VL limits of CV <35%. 
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Table 3.5: CAP/CTM: Adult OBS VL performance (SO and CV) in 5 VL categories. 
Plasma VL OBSVL 
Intra precision Inter precision 
VL category Panel log copies/ml SO %CV SO %CV Total SO (log) member {log! {co~ies/ml! {log! {co~ies/ml! 
undetectable 0.00 undetectable 0.13 31 .32 0.08 19.60 0.15 
2 0.00 undetectable 0.31 86.02 0.34 76.79 0.46 
:53 log 3 1.63 43 0.11 23.94 0.25 71 .92 0.28 
4 1.91 81 0.03 7.25 0.16 30.99 0.17 
>3 -:54 log 5 3.08 1208 0.11 27.89 0.37 117.72 0.39 
6 3.64 4347 0.10 21 .75 0.36 113.47 0.37 
>4 -:55 log 7 4.46 28521 0.14 31 .29 0.14 36.80 0.20 
8 4.34 22122 0.04 9.34 0.10 20.14 0.11 
>5 log 9 5.20 158301 0.03 6.77 0.07 17.03 0.08 
10 5.39 245999 0.05 10.64 0.08 18.65 0.09 
Red highlight: SD>log 0.19; CV >35% 
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Table 3.6: CAP/CTM: DBS VL intra precision investigated in children in 5 VL categories using plasma VL as the reference 
standard. 
Plasma viral load OBS viral load 
Viral load Panel %CV n n valid 
category member log copies/ml SO (log) (copies/ml) replicates results tested obtained 
1 1.30 19 0.10 22.95 5 5 
undetectable 
2 1.30 19 0.19 44.96 5 5 
3 2.58 382 0.12 23.30 5 5 
:::;3 log 
4 2.30 199 0.30 77.84 5 5 
5 3.31 2046 0.24 66.11 5 5 
>3 -:::;4 log 
6 3.41 2574 0.07 15.83 5 5 
7 4.81 64919 0.12 29.75 5 5 
>4 -:::;5 log 
8 4.16 14484 0.16 39.77 5 5 
9 5.65 392215 0.12 26.40 5 5 
>5 log 
10 5.53 336489 0.07 17.03 5 4 
Red highlight: SD>log 0.19; CV >35 
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3.3.3.2 m2000 OBS VL PRECISION 
On the m2000, the SO and CV values overall are higher than the plasma limits of 
acceptance <0.1910g copieslml and <35% across the VL categories due to several 
undetected VL in OBS which had quantifiable plasma values. The OBS VL SO is 
acceptable in 2/10 (20%) of patients and the % CV is only acceptable in the plasma 
undetectable category and in one patient with plasma VL>5 logs in children (Table 
3.7) . 
In comparing the performance of 1 OBS and 2 OBS, the intra-variability is less 
variable than inter-variability in both instances in samples from adults demonstrating 
that overall, 2 OBS may have performed better than 1 OBS across all the VL 
categories (Table 3.8 and 3.9). The total SO is acceptable in the lowest and the 
highest VL categories irrespective of the number of spots used (Table 3.8 and 3.9). 
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Table 3.7: m2000: Child OBS VL intra-precision in 5 viral load categories using 
plasma VL as the reference standard . The OBS viral load SO and CV are only 
acceptable in the plasma undetectable category and in one patient with plasma 
VL>5 logs. 
Plasma viral DBS viral load 
load 
Intra ~recision 
Viral load Panel copies/m SO %CV n n valid 
category memb log I (log) (copies/ml) replicates results 
er tested obtained 
undetectab 1.30 19 n/a# n/a# 5 5 
Ie 2 1.30 19 n/a# n/a# 5 4 
3 2.06 116 0.27 108.42 5 5 
<3 log 
4 1.93 86 0.92 208.19 5 5 
>3 log <4 5 3.70 4996 0.21 45.60 5 5 
log 6 3.50 3181 0.22 75.84 5 5 
>4 log <5 7 4.23 16989 0.14 97.82 5 5 
log 8 4.61 40735 0.17 38.32 5 4 
9 5.86 725937 0.09 19.65 5 5 
>5 log 
10 6.06 392212 * 5 0 
*SO and CV were not calculated as there were <3 valid results for the replicates in this category 
# SO and CV cou ld not be calculated as there was no difference between plasma and OBS VL values 
in the undetectable category 
Red highlight: SO>0.19; CV>35% 
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Table 3.8: m2000: Adult DBS (1 spot) precision in 5 VL categories using plasma VL as the reference standard. 
Plasma Viral load OBS Viral load 
Intra ~recision Inter precision 
Viral load Panel copies/m SO %CV SO %CV Total SO n n valid 
category membe log I (log) (copies/ml (log) (copies/ml) (log) replicates results r } tested obtained 
1 0.0 0.0 0.00 n/a# 0.00 n/a# 0.00 10 9 
undetectable 
2 0.0 0.0 0.00 n/a# 0.00 n/a# 0.00 10 9 
3 2.3 196 1.67 139.55 1.79 173.21 2.45 10 9 
<3 log 
4 2.2 169 1.64 155.68 1.69 117.58 2.35 10 8 
5 3.8 6135 0.14 31.68 1.66 111 .78 1.67 10 7 
>3 log <4 log 
6 3.5 3055 1.67 200.24 1.46 73.95 2.22 10 9 
7 4.5 31198 0.08 18.79 0.56 81 .73 0.57 10 8 
>4 log <5 log 
8 4.5 35299 0.10 80.74 0.41 57.07 0.42 10 9 
9 5.2 142550 0.03 6.18 0.71 76.57 0.71 10 6 
>5 log 
10 6.1 1167215 0.04 8.49 0.02 114.07 0.04 10 10 
# %CV could not be calculated as a ratio of the SO and mean since the SO and mean values were O. These values were zero because they were not-
quantifiable, and listed as undetectable. 
Red highlight: SO>0.19; CV>35% 
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Table 3.9: m2000: Adult DBS (2 spot) precision in 5 VL categories using plasma VL as the reference standard. 
Plasma viral load DBS viral load 
Intra ~recision Inter ~recision 
Viral load Panel SO (log CV CV Total n n valid log Copies/ml copiesl SO (log) (copiesl SO replicates results 
category member copies/ml) ml ml! (log! tested obtained 
1 0.0 0.0 0.00 n/a# 0.00 n/a# 0.00 10 7 
undetectable 2 0.0 0.0 0.00 n/a# 0.00 n/a# 0.00 10 7 
3 196 2.3 1.88 97.61 1.82 136.33 2.62 10 9 
<3 log 4 169 2.2 1.44 223.61 1.88 121 .64 2.37 10 9 
5 6135 3.8 0.07 17.88 2.00 94.56 2.00 10 9 
>3 log <4 log 6 3055 3.5 0.21 58.74 1.65 120.36 1.67 10 8 
7 31198 4 .5 0.06 13.56 2.23 74.24 2.23 10 9 
>4 log <5 log 8 35299 4 .5 0.18 38.40 0.10 23.88 0.20 10 8 
9 142550 5.2 0.06 13.38 0.12 25.77 0.13 10 9 
>5 log 10 1167215 6.1 0.12 29.11 0.07 15.16 0.13 10 8 
# %CV could not be calculated as a ratio of the SO and mean since the SO and mean values were O. These values were zero because they were not-
quantifiable, and listed as undetectable. 
Red highlight: SO>0.19; CV>35% 
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13.4 DISCUSSION 
Plasma VL molecular tests are used in clinical practice to confirm an HIV infected 
status in newly diagnosed children and to monitor disease progression in HIV-
infected patients on ART [89]. Some limitations of plasma VL testing include the 
requirement for cool transportation and storage conditions to maintain HIV RNA 
integrity and the relatively large sample volumes (0.2ml - 1.0ml plasma) required 
from the paediatric population. DBS have been investigated as an affordable and 
more practical alternative sample type for VL testing with potential to increase 
access to testing. The relevance of a study of DBS VL accuracy would be an 
expansion in the diagnosis of infants in resource limited settings. The study of DBS 
VL precision would provide evidence on the feasibility of replacing plasma VL with 
DBS VL for HIV monitoring in the paediatric (and adult) population in South Africa. 
Evidence from a multicentre study of DBS RNA stability demonstrated that HIV RNA 
in DBS is stable at ambient temperature (15-30° C) for one year [8]. Based on this 
evidence, rural areas would be able to submit DBS samples for VL testing without 
refrigeration, as RNA would be stable between sample collection and testing at 
locations in which laboratory services are highly centralised. Overall , DBS RNA is 
stable during storage, provided that high humidity is avoided (by inclusion of 
desiccant sachets in the packaging) and that storage temperatures do not exceed 
3TC [98] . DBS samples require storage at -70°C to preserve HIV RNA if samples 
were to be stored for more than a year [8]. The DBS RNA in this laboratory study 
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was considered to be stable for the duration of the study as DBS samples were 
stored at room temperature and tested within a year of collection as described in the 
multicentre study of DBS. 
In comparing the accuracy of DBS VL to plasma VL on the CAP/CTM platform the 
finding that DBS VL were detectable and quantified where plasma VL were 
undetectable was consistent with the findings in other studies of DBS VL [71,74,99] . 
Amplification of proviral DNA from peripheral blood mononuclear cells (PBMC cells) 
and the tota l nucleic acid extraction methodology contributed to the total DBS VL [77, 
100, 101]. It is suggested that DBS samples treated with DNase during sample 
preparation would better reflect the true VL since DNA in the sample would be 
destroyed thereby allowing for RNA to be quantified exclusively [100]. However, 
methods that require multiple test kits for sample preparation add to the cost of the 
test and may not be feasible for resource constrained settings nor for high 
throughput laboratories in which minimal manual sample preparation is preferred. 
The CAP/CTM would be highly sensitive for confirming the presence of HIV and 
therefore ideal to use as confirmation of a positive HIV infection status in children 
less than 18 months old with an initial positive HIV DNA PCR. In contrast to the 
CAP/CTM, the m2000 DBS HIV VL assay was impartial to proviral DNA due to the 
predominantly "RNA only" extraction of this assay and therefore amplification of 
predominantly HIV RNA nucleic acids [95]. DBS samples matched plasma samples 
that were RNA undetectable in 100% of cases from adults and children . The clinical 
application of this finding for routine HIV monitoring is that DBS VL on the m2000 
could be used to reaffirm treatment success. Due to the effect of proviral DNA, 
91 
patients on ART monitored on the CAP/CTM platform using DBS are unlikely to 
attain an undetectable VL result, despite the success of their treatment regimen as 
based on the evidence in this study. 
The DBS and plasma VL method comparison on both the CAP/CTM and the m2000 
platforms was illustrated in the Bland Altman plots. The CAP/CTM did not show good 
agreement overall between the two sample types tested, as 29.10% and 23.07% 
percentage similarity CV in children and adults respectively was obtained. The 
greatest bias (least accuracy) was obtained at <310g and undetectable plasma VL 
categories. Overall, a negative bias was obtained demonstrating that the DBS VL 
measurements were higher than the gold standard plasma VL measurements in 
most of the VL categories. The least bias (greatest accuracy) was obtained in the 
higher VL category at VL >510g . 
The m2000 comparison of plasma and DBS VL accuracy also did not demonstrate 
good agreement between the two sample types tested . The percentage similarity CV 
was lower in children (16.11 %) as compared to the percentage CV in adults, but 
similar percentage CV values were obtained in the 1 spot (24.59%) and two spot 
(25.77%) comparison on DBS samples from adults. The greatest bias (least 
accuracy) was obtained at plasma VL <410g copies/ml. Overall, a positive bias was 
obtained demonstrating that the DBS VL measurements were lower than the gold 
standard plasma VL measurements in most of the VL categories. The least bias 
(greatest accuracy) was obtained where plasma VL were undetectable. The clinical 
implication of using the m2000 and CAP/CTM platforms for monitoring HIV VL on 
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DBS is that the platforms may not be used interchangeably. Patients tested on either 
platform would have to be retested on the same platform since DBS VL 
measurements on CAP/CTM produces higher VL values than on the m2000. 
The m2000 in this study did not detect VL in 39 combined adult and child DBS 
samples in which RNA was detectable at levels of <410g copies/ml in the 
corresponding plasma sample and is consistent with the findings in two other studies 
in which 25 DBS samples were HIV RNA undetectable although the matched plasma 
samples had low levels of detectable RNA in samples from infants [71] and adults 
[76]. A lower limit of detection or threshold of 4 log copies/ml in this study would 
minimise the number of false negative DBS VL measurements on both the 
CAP/CTM and m2000 platforms. The threshold in this study is much higher than the 
3.010g [74, 79] and 3.7 log [76, 78] suggested in other studies, but consistent with the 
threshold described in a study of DBS VL for early infant diagnosis [72] . The WHO 
guidelines for managing virological failure describes a threshold of 1000 copies/ml 
(310g) when testing on plasma. The sensitivity of DBS VL is reduced, therefore a 
higher threshold at 3000-5000 copies/ml (3.5-3.710g copies/ml) is recommended 
when testing on DBS [62] , which fits in with the threshold described by Neogi [78] 
and Garrido [76]. It can be concluded that DBS VL thresholds vary depending on the 
nucleic acid extraction techniques and the platforms used for RNA amplification [63 , 
91]. 
Meaningful comparisons of studies of DBS VL are difficult mostly due to a lack of 
standardisation of methodology, the use of modified commercial kits, and varying 
93 
platforms and methods for RNA extraction and detection [91, 98]. Studies have 
reported better correlation between plasma and DBS when the EasyQ boom 
technology was used for HIV RNA extraction [74, 76, 100]. A study by Monleau 
confirmed that the boom extraction method used on NucliSens EasyQ-EasyMag 
yielded the most accurate and sensitive RNA extraction as compared to four other 
RNA extraction methods on DBS [100]. Resource limited setting are often not 
equipped with multiple VL platforms and therefore are restricted to using a single 
supplier for extraction and amplification for VL monitoring. This study investigated 
two platforms in their extraction and detection equipment pairs. During the m2000 
manual extraction method the disintegration of DBS in the lysis buffer during the 
incubation period may have contributed to the large number of errors obtained on 
this platform. The CAP/CTM manual extraction method yielded minimal errors 
making the CAP/CTM the better choice for sample extraction in this study. 
Although only 78.7% of valid DBS VL results were obtained on the m2000 as 
compared to the 100% on CAP/CTM, both platforms demonstrated 100% specificity 
in diagnosing HIV in 6 week old HIV-exposed, HIV-uninfected infants. The high 
specificity obtained in this study is consistent with the 100% specificity obtained in 
two other stud ies [70, 71] in which DBS were evaluated for early infant diagnosis and 
VL monitoring. The clinical application of zero false positives DBS VL obtained is that 
clinicians could utilise these two platforms for diagnosis of HIV in adults and children 
without the need for a threshold. 
The precision of DBS VL was below standard for VL monitoring. DBS VL may not be 
useful for VL monitoring unless possibly performed in a semi-quantitative way. The 
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number of errors on the m2000 platform need to be resolved before the platform can 
be used for clinical DBS samples. In this study of DBS VL precision on the CAP/CTM 
and m2000 platforms, DBS intra-precision showed less variability than inter-
precision. The SD and CV values overall were lower for intra-precision 
measurements in adult samples. Testing of HIV monitoring emulates inter-precision 
(except for biological variation) . Just as samples are tested in different batches over 
a period of time, so too, patient VL are tested at the beginning of ART and thereafter 
periodically over a few months to monitor changes in VL levels which indicate patient 
response to therapy. Changes in serial measurement of RNA are significant to the 
caregiver as the laboratory findings should correlate with patient clinical presentation 
[85]. DBS VL values on CAP/CTM were higher than DBS VL values on m2000 and is 
consistent with an evaluation of plasma VL precision on these two platforms [102]. 
Based on these findings, patients tested longitudinally during VL monitoring cannot 
be tested interchangeably on the two platforms [102], no matter the sample type. 
The investigation of the accuracy of m2000 2 spot versus one spot demonstrated 
that the use of 2 spots yielded mean percentage similarity values closer to 100% 
(exact match) to the gold standard than 1 spot for VL testing on m2000. The 
interpretation of this finding is that the m2000 may be difficult to use for paediatric 
DBS VL monitoring if inadequate sample such as less than 2 full spots of DBS 
sample is received. The CAP/CTM tests adult and paediatric VL in a single DBS and 
no technical errors were obtained. 
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This study of DBS VL had several limitations. One such limitation was that DBS were 
made from EDT A blood (ideally in the real world DBS cards would be spotted directly 
from patient by finger- or heel-pricks) and possible EDTA interference was not 
accounted for in this study. A further limitation was the small sample size comprising 
a total of 20 adults and 20 children that were tested across five VL categories and 
only two patients were tested in each VL category. This is a super low sample size, 
and claims that -4 log copies/ml should be used as a threshold need further 
investigation since only four patient samples were tested above and below that cut-
off. Future work with a larger sample number is needed to reaffirm and establish 
whether this threshold can be used confidently. No direct comparison of the two 
platforms was made (using the same samples) as the samples tested on the 
CAP/CTM platform were not the same patients that were tested on the m2000 
platform. 
A multicentre study on DBS VL to standardise nucleic acid extraction and to 
establish a universal threshold is needed until manufacturers of VL technologies are 
able to develop apparatus specifically for DBS VL testing [90]. Alternative strategies 
to improve access to VL testing such as point of care plasma or whole blood VL 
would be more appropriate than DBS VL testing since plasma VL testing is already 
the gold standard. Perhaps point of care plasma VL testing [29] would reduce the 
problems that are incurred with sample transportation and storage to testing sites. 
An ideal VL test for a resource limited setting would be performed on whole blood, 
with RNA extraction and or DNAse treatment for monitoring, but whole blood and 
total nucleic acid detection for diagnosis. 
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13.5 CONCLUSION 
The DBS VL testing method can be used to make a diagnosis of HIV infection in 
infants due to the high specificity obtained on both platforms. In particular, the 
CAP/CTM assay would be the preferred platform for confirmation of HIV infection in 
infants because the sensitivity of the test is increased by proviral DNA. In the era of 
more and longer ARV regimens for PMTCT, which consequently lowers RNA as 
described from daily dose Nevirapine, detection of proviral DNA is relevant. 
However, HIV-infected infants on ART cannot be monitored accurately on DBS 
without a VL threshold being considered. The DBS VL threshold for both platforms in 
this study, using the extraction and detection instruments in their pairs as supplied by 
the manufacturer, was -410g copies/ml. Furthermore, DBS VL do not perform within 
the plasma precision limits and inter precision performed worse than intra precision 
on both platforms, therefore longitudinal clinical monitoring of patient response to 
ARVs may not be feasible. The m2000 platform performs more accurately and 
precisely on two DBS spots as compared to one DBS spot. 
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CHAPTER 4 
CONCLUSION TO DIAGNOSIS AND MONITORING OF 
HIV IN INFANTS 
Improvement in technologies that aid the detection and monitoring of infection is 
essential in the battle against HIV, which has already claimed numerous lives of 
women and children. Many of the evolving technologies would essentially need to be 
functional in resource-limited settings. Although newer rapid HIV tests such as DC 
address the cold storage issue in resource limited settings by changes in design that 
allow storage of the test at room temperature, the greater challenges of early 
identification of infants at risk of acquiring HIV and detection of acute HIV infection at 
point of care remain. A fourth generation rapid test intended for detection of early 
infection requires further development to enhance the sensitivity of the test and 
offers no advantage over currently available tests. 
Technological advances in presently available HIV VL monitoring platforms are 
needed before DBS VL can replace the gold standard plasma VL method based on 
the findings in this study. Although DBS VL were shown to compare with plasma VL 
(with the proviso that a threshold is used) and this has been demonstrated in many 
studies, correlation data is not sufficient to draw conclusions that DBS VL can be 
implemented with confidence for HIV monitoring for patients (adults and children) on 
treatment. The findings in this study of poor DBS VL precision, despite the limitations 
of the study, does not support the implementation of the DBS VL method for HIV 
monitoring. The DBS VL method, however, can be used with confidence to ascertain 
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an HIV status on treatment na"lve patients, based on the high specificity obtained in 
this study. 
Since technology continues to playa major role in achieving goals such as reduced 
infant mortality and improved HIV health care for infants in South Africa, other 
alternatives that address the gaps in diagnosis and patient management require 
ongoing investigation. 
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Background: HIV rapid tes ts (RT) play an important role in tackling the HIV pandemic in 
South Africa. Third generation RT that detect HIV antibodies are currently used to diagnose 
HIV infection at the point of care. Determine Combo (DC) is the first fou rth generation RT tha t 
detects both p24 antigen (p24Ag) and HIV an tibodies (Ab), theoretically reducing the window 
period and increasing detection rates. Early detection of maternal HTV infection is important 
to mitigate the high risk of vertical transmission a~ociated with acu te mate rna l infection. 
Objectives: We assessed the performance of the DC RT against third generation RT in 
antenatal and post-pa rtum women. 
Methods: Third generdtion RT Advance Quality and Aeon were used in a ~riaJ algorithm 
to diab'T'lose HIV infec tion in antenatal and post-partum women over ix months at a tert iary 
hospita l in Johannesburg. South Africa . This data provided the reference against which the 
DC RT was compared on p lasma and whole blood .sa.mple~. 
Results: TIlt' 1019 participants comprised 34S (34%) an tenatal and 674 (661%) post-partum 
women. Ninety women (8.8%) tested HIV-positive of whom 59 (66%) were tested antenatally, 
and 31 (34%) post-partum yielding prevalence rates of 17.1% and 4.6% respectively_ The 
sensitivity and specificity of the Ab component of DC on plasm" antenata lly was 100% 
(93.8% - 100%) and 100% (98.6% - 100%) respectively and post-partum was 100% 
(88.9% - 100%) and 99.6% (98.8% - 99.9%) respectively. One false positi ve and not a single 
true positive p24Ag was detected . Of 505 post-partum women who tested HIV-nt!gative 6-12 
months prior to enrolment, 12 (2.4%) seroconverted. 
Conclusion: Tht> fourth generation OC offered no advantage over current third generation RT 
in the d i<lgnosis of HTV infection. 
Introduction 
HIV rapid tests (RT) play aJ1 important role in addressing the HJV and ArDS pandemic in South 
Africa. They can be cond ucted a t the point of care because they a re easy to perform and requi re 
no special ins trumentation. The advantage of poin t of care RT is tha t the patient can receive their 
HIV tes t resul t at the sa me climc visit, which red uces loss to follow-up and fast tracking patients 
into care .1 RT are less costly than laborator)'~based assay::. fo r antibod y (Ab) det(..>('tion namely 
HIV Enzyme-linked I mmu.nosor~nt ASScl YS (ELISA) and vi ral de tection namely HIV DNA or 
RNA or p24 Antigen (p24Ag). 
In South Africa. pregnant women are offered counselling and tes ting fo r HI V at their firs t 
antenatal clinic visit and at 34 weeks of pregnancy if their initial I-II V tes t was nega tive. l Women 
at the Rah ima Moosa Mother and Child I lo.pital (RMMCH) in Johannesburg, South Africa are 
also offered an HIV test immedia tely post-partum if their l·ll V s tatus is unknown or more than 
six weeks have elapsed since their last negative I-UV tes t. The i.mportance of HJV retesting has 
been demonstrated by a South African study in which 3.4% of women who tes ted HIV-negative 
at thei r first antenatal visit, sub~equently seroconve rt~d during pregnancy or within a year after 
de livery. \ The Advance Q uality HIV Rapid Test On Tec Prod ucts, Inc. Xianen, China) and Acon 
HTV 1/ 2/ 0 Tri-Iine R.:lpid Test (Aeon Laboratories, mc., San Diego, USA) are currently used 
to d iagnose 1-IlV infection in womell in Prevention of Mother- to-Child transmission (PMTCT) 
p rogrammt!s in Gauteng province, South Africa. These third generation RT detect HIV Ab that 
are produced in response Lo th(' virus by a serial testing algorithm as recommended by tht.' South 
African PMTCT guidelines! (Figure 1). Advance Quality is used to scrt!en for HIV Ab and if 
positive, the Acon test is performed to confirm HIV status. Laboratory-based HI V ELISA and, less 
commonly, vira l det~tion dssa yS can be used as a tiebreaker to confirm an HIV sta tus if serial RT 
results are- discordant .2 
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fiGURE 1: Study methodOlogy: The Determine Combo rapid test (DC RT) was 
perfOlmed at the same ome as the routi ne algorithm 
The Determine Combo HlV-I/2 Ag/ Ab Combo Test 
(DC) (Inverness Medical, Japan Co.,Ltd) is the first fou rth 
generation RT and can be performed on e ither plasma or 
whole blood samples.' It is an enhancement of the third 
generation tests as it can detect both HIV Ab and p24Ag in a 
single test. ' The p24Ag is a marker of early HIV infection and 
is detectable in blood during the window period before HTV 
Ab become detectable' The DC RT is reported to have the 
potential to identify HIV infection five days (range 2- 20 days) 
earlier than third generation RT. The reported sensitivity and 
specificity of the DC Ab component is 100"10 (95% confidence 
interval 98% - 100%) and 100% (95% confidence interval 
98.2% - 100%) resp<'ctively and the sensitivity of the p24Ag 
component is 86.6% (95% confidence interval 76% - 93.7%). ' 
Detection of early HIV infection during the window period 
of third genera tion RT would a llow more maternal HIV 
infections to be detected . Furthermore, during early maternal 
HTV infection the levels of the virus in the blood are at their 
peak and the risk of transmission to the infant during birth 
and breast-feeding is very high.' Detection of early infection 
would allow more women and their infants at a high risk of 
vertical transmission to access PMTCT. 
The performance of the fourth generation HIV DC RT in 
diagnOSing HIV infection status antenatally and in the early 
post-partwll period in comparison to the third generation 
HlV RT in routine use at public healthcare facilities in 
Gau teng, South Africa was assessed . TI'le advantage offered 
by the DC RT over thi rd generation RT of detecting HIV 
infection earlier to increase identification of women at a high 
risk of verticaJ transmission for PMTCT was investigated . 
Methods 
Study participants 
Women attending the antenatal clinic and delivery unit 
at RMMCH in Johannesburg were invited to test fo r HIV 
infection . Counsellors interviewed the participants to 
establish their HIV status. Women with an unknown HlV 
sta tus, those who had tested HIV -negati ve more than 6 weeks 
previously and those who reported an HlV-posi tive status 
but had no doculTlent~d evidence thereof on their maternal 
card were invi ted to participate in the study. Women with 
a documented HIV·positive status were excluded. Written 
informed consent was obtained from all participants who 
agreed to test for HIV infection . Eth ics approva l (M091119) 
for the study was granted by the Hu man Research Ethics 
Committee at the University of the Witwatersrand, 
Johannesburg. 
Sample size 
The prevalence of HIV infection amongst antenatal 
women in Gauteng province, South Africa in 2008 was 
29.9% (95% confidence interval 28.4% - 31.2%)' ; however, 
the prevalence of HIV inJection amongst women testing 
antenata lly and shortly after delivery at RMMCH in 2008 
was lower at 15% and 4.2% respectively since women with 
a known, documented HIV-positive status are excluded 
and proportionately more women fall into this category 
after delivery than antenata lly. ,,' From R.J\1MCH HIV testing 
records we expected app roximately 200 women to present 
for testing per month wi th a prevalence that depended on 
the proportion of women testing before or after delivery. A 
convenience sample of a ll women eligible for HIV testing at 
RMMCH who agreed to participate in the stud y was chosen 
to assess the number of additional women the DC RT could 
identify as being infected over a 6-month period on plasma 
samples. For assessment of whole blood samples, the Centers 
for Disease Control and Prevention recOInmendations to 
include samples from at least 20 HlV-infected and 80 HIV-
uninfected women were followed.l! 
HIV testing 
Five millilitTes of whole blood was drawn into an 
ethylenediamiJ1Ctetraacetic (EDTA ) tube for testing at the 
study site. Samples were centrifuged to obta in plasma on 
w hich the RT were performed . DC RT were performed on 
whole blood prior to centrifugation. All RT were p<'rformed 
within one hour of blood sampling by a single laboratory 
technician accord ing to the manufacturer's instructions. 
Third generation RT Advance Quality and Aeon were used 
seria lly on plasma according to the national testinga lgorithm2 
to diagnose HIV infection (Figure 1) and were the reference 
standards against which the DC results were compared . 
Interpretation of rapid test 
The DC is a qualitative immunochromatographic test which 
is read visua lly. The test s trip is divided into an HIV Ab 
window and an HIV p24Ag window. The presence of a pink 
line in e ither or both of the w indows is indica tive of HIV 
infection. Each test strip incorporates a procedural positive 
con trol and the test is considered va lid only if the positive 
control is detected . 
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The women received their RT results and post-test 
counselling wi thin foUI hours of blood sampling. Patients 
that were HIV-positive on both third generation RT were 
referred to antiretrov iral treatment clinics. The results of the 
DC RT were not disclosed to the pa tient. However, where the 
thi rd generation and DC HIV Ab RT resul ts were discordant, 
samples \,\'ere refe rred for confirmatory fo urth generation 
ELISA (ARCHITECHT'" HI V Ag/ Ab Combo assay; Abbott 
Diagnostics; Wiesbaden, Germany). Patients that had 
detectable p24 Ag on DC were followed lip with three 
confirmatory tests that is viral detection assay (Vironostika 
HrV-l Antigen; bioMerieux; Bosiend, The Netherlands), vi ral 
load testing (NucliSENS EasyQ-EasyMag HI V-l, version 1.2 
assay; bioMeriellx; BoxteL The Netherlands) as well as fourth 
generation ELISA. Disclosure of the patient's HIV status was 
delayed for 48 hours. 
Analysis 
Likelihood ratios were calculated instead of predictive 
values because predictive values depend on prevalence and 
a difference in J-II V "revalence was anticipated between 
women tested in the antenatal and post-pa rtum period . 
A positive likelihood ratio (sensitivity/ (l - specifiCity)) 
> 10 strongly predicts HrV-infection, whereas a negative 
likelihood ratio «('I - sensitivity) / specificityl < 0.1 virtually 
excludes the condition . 
Results 
Between March and August 2010, 1019 (92.7%) of the 1099 
women eligible fo r HIV testing at RMMCH were enrolled in 
the study. Of the 1019 participants, 345 (33.9%) were tested 
antena tally and 674 (66.1%) post-partum. According to the 
routine third generation RT diagnostic algori thm, 90 (8.8%) 
of the 1019 patients tested positive for HIV infection without 
• 
the need to use a tiebreaker. Of the 90 HIV-infected women, 
59 (65.6%) were antenatal and 31 (34.4%) were post-partum. 
The HfV preva lence amongst the women tested antena tally 
was 17.1 % and those tested post-partum was 4.6%. 
Know ledge of the women 's HIV status prior to undergoing 
HIV testing on the study was documented for those tested 
in the early post-partum period only (Table 1). Of the 505 
women that had reported or tested HIV-negative between 
6 and 12 weeks prior to study enrolment, 12 (2.4%) tested 
posi ti ve demonstrating that new Hrv infections were 
occurring in this population. Not all of these women had 
their nega tive HIV status documented on their maternal 
record and the possibility that some reported their status 
incorrectly cannot be excluded . 
The DC RT was performed on plasma sample o f the 1019 
women and on whole blood samples on a subset of 380 women. 
All 1399 tests performed demonstrated posi tive control strips 
therefore no DC RT was invalid . SenSitivi ty, specificity and 
likelihood ratios for the DC RT were calcula ted separately for 
women who were tested antenatally and post-partum (Table 
2). The sensitivity of the DC RT Ab component was 100"/0 111 
all groups of women tested irrespective of the sample type. 
The speCificity of the DC RT Ab component in women te.ted 
post-partum was less than those tested antenatally. 
The DC RT results concurred with the third generation RT 
results in all patients except for three post-partum women on 
whom both plasma and whole blood samples were tested. In 
two patients the Ab component of the DC RT was positive on 
both their plasma and whole b lood samples but negative on 
both third genera tion RT. Labora tory based fourth generation 
ELISA tests on both cases were negative confirming two false 
positive DC HlV Ab results. 
TABLE 1: HIV status of post-partum women pnor to enrolment and after testing with the National testing algOrithm. 
Reported or documented HIV statW$ Time since last test HIV-infKted HIV-uninfected Pen::entall!: positive 
(week5) 
Negati .... e 6-12 505 12 492 2.' 
> 12 107 104 2.8 
Unknown HIV status 58 ,. ' 3 24.1 
Poslnve: reported but not documented 50.0 
Toyl 
". 31 641 .. 
lI, umple$lle. 
Women of unknown HI\! status had oil hllh prev.llience of HlV Infttetlon H. lf of Ihe women who reported I posItive HIV satus Dut hid no document.tIOn to substintl.te I posltl..,e HIV te st, lesl l!d 
HIV-ne"tlve. 
TABLE 2 : Performance of Determin e Combo rapid test HIV antlbody (DC RT Ab) component in plasma and whole blood samples In women tested antenatally and 
post-parturn . 
Timetestwu Sample type: Prevalence Determine Sensiftvity 95-;' confidence LR_ Determine 
conducted Combo HIV interval ComboHIV 
Ab+/ HIV+ Ab-/HIV-
Antenatal Plasml 345 17.1 59/59 100 93.8-100.0 569.2 286/2 86 
Whole blood 151 59/59 100 93.8-100.0 184.5 92/92 
Post-pilrtum Plasma 
." •• 33/3lt 100 88.9-100.0 321.5 641 /64 3 
W hole blood 219 32/30t 100 88.6-100 0 99.5 197/199 
n, umpleslu . 
t, FOllse POSItlYI! resul15 obl'lned In 2 women on both sample types One .dditloni i women!f\ th" , roup tested HIV o24A& f.lse pollnYe on DC. 
HI\.'+.nd HIV· Ife HIV-Inf.,ted Ind HIV-un,nfected wome" respectIVelv as defi"ed by the third aemerano" ~ptd test {RTralgonthm . 
LR+ I nd LR· are the posItive ."d M aatwe hkol!hhood ' i1t1os 
Specificity 95-/. confidence lR· 
interval 
100.0 98.6-100.0 
100.0 95.9-100.0 
99.7 98.9-99.9 
99 .0 96.4-99 .7 
The hiah posltllle likelihood .atlos (lJI.+ ).nd low rleCltlW likelihood ratios ILR-) demonstrate th.t Ihe Determ ine Combo rapid test was iii stron& predtctor of HIV·lnfect'1on In Hiv positive women ~nd 
eKCluded HIV mfectlon in HIV·uninfecad women respectively. rec"rdlen of Simple type and tlmtnl of !ntlnl. 
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The DC p24Ag was reactive on plasma and U,e whole blood 
of only one patient of all 1019 women tested . ThIs patient 
was suspected of having an early infection since botil third 
generation RT and the DC Ab component tested negative. 
However tile laboratory based fourUl generation HJV ELISA 
was negative and the v iral load was undetectable indicating 
a false positive DC p24Ag result. ' 0 p24Ag bands on DC 
were obtained on any of the 90 HIV-infected women nor was 
a single case of early HfV infection detected . 
Discussion 
ConSidering tile high enrolment rate, the sample of women 
tested in this study is likely to be representative of women 
who are tested for HIV-infection at RMMCH Over half a 
yea r. Furthermore, tile HIV prevalence of 17.1% and 4.6% 
in women testing antenatally and immedia tely post-partum 
respectively is similar to a previous description at RMMCH.I.I 
An HIV prevalence of 24.1% in women of unknown J-lIV 
status is also comparable to tile 28% prevalence previously 
described in 2008. However, the seroconversion rate in post-
pa rtum women of 2.4% is less than the previously described 
rate of 4.5%.lO The implication that new maternal infections 
are occurring in this population remains. In practice, a 
positive p24Ag DC test wouJd require confirmation of early 
seroconversion by fourth generation EUSA or nucleic add 
testing which may delay initiation of PMTCT. In contrast to 
,1 study that reported 16% in va lid DC RT tests due to failure 
to detect the controI," all DC RT in tilis study were valid 
possibly because we used fresh, not stored samples. 
Sensitivity and specificity of the DC RT was comparable to 
plasma and whole blood in contrast to a p re\~ous report tilat 
demonstrated lower sensitivity of the DC RT in whole blood 
compared to serum samples." The sensitivity of tile fourth 
generation DC RT in detecting J-lIV Ab was comparable to 
tilat of tile reference tilird generation RT in antenatal and 
post-partum women in plasm,' and whole blood samples. 
The specificity of the DC RT in detecting HIV Ab was slightly 
reduced in whole blood and plasma in post-partum women 
owing to the false positive results in two women, but was 
still witilio the World J-lealtil Organization recommended 
range of more than 98%.1 \
The fourtil generation DC RT did not detect a single true 
positive p24Ag, even in tile 90 HIV-infected women. The 
sensi tivi ty in detecting p24Ag in HIV-infected women was 
0% as compared with tile claim of 86.6% obtained on HIV-
infected samples.' The reason for this may be til.t p24Ag 
forms inlmune complexes wi th HIV Ab and thus no free 
p24Ag is present fo r detection by the DC.' The DC RT 
tilerefore did not identify any new cases of maternal HIV 
infection over the 6 montil s tudy period . Possible reasons for 
tilis include that tile sensitivity of tile DC p24 Ag component 
is poor or that no women with acute HIV infection were 
enrolled . The former concurs with previous reports that the 
DC RT p24 Ag component lacks sensitivity particularly where 
levels of p24 Ag are below 400 pg/ mL. I2·" Additionally, the 
p24Ag component of the DC RT has reduced sensitivity 
in comparison to oLher fourth generation vira l detection 
assays,' some of which are able to detect p24Ag at levels of 
4 pg/ mL - 5 pg/ mL." The initial laboratory based 
p24Ag assa),s also demonstrated poor sensitivity that was 
subsequently improved by denaturation of tile in,mune 
complex and Signal amplification to enhance p24Ag detection." 
A limitation of this study is tilat the incidence of HIV 
infection in women undergOing HIV testing at RMMCH is 
unknown therefore, although new maternal infections were 
demonstra ted, it is possible that no women with acute HIV 
infection were enrolled during the short window period 
before HIV Ab and subsequent immune complex fo rmation. 
Nevertheless, the DC RT did not identify any new infections 
over tilose identified by tile 3rd generation RT assays over six 
months in the RMMCH PMTCT programme. 
Conclusion 
The DC RT failed to demonstrate any advantage over 
third generation RT currently in use in our setting in either 
detem'ining HIV infection status or in identifying recently 
infected women. Improved sensitivity of p24 Ag detection is 
required before fourtil generation RT will offer an advan tage 
over their tilird generation counterparts in tile field . 
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HIV R EPORTS 
Performance of the First Fourth-generation Rapid Human 
Immunodeficiency Virus Test in Children 
Kapila Bhawan , ND* and Gay le G. Sherman, MD. PhD* t:f: 
Abstract: Diagnosing HIV infection in infants by p24 an ligen detection at 
point of carc is likely (0 reduce infa nt morbidity and mortality. A fourth-
generation r.:Ipld lest evaluated on 202 stored samples from chi ldren of 
known age and clinical presentation demonstrated a sens lli vi ty of <1% for 
detecting p24 antigen in 6 1 HIV-infectcd infanlS and demonstrated 100% 
sensit ivi ty and specific ity for detectmg HIV antibodies in infants aged 6 
months and younger. 
Key Words: children. human immunodeficiency VITUS. fourth generation, 
p24 antigen, mpid te st 
\ Pediarr Infecl Dis J 20 13:32: 486-488) 
Point of care (POC) tests for diagnosing HIV infection in infa nts in resourct:-constrained settings may reduce HIV-related infant 
mortality by improving detection of infected infants and facilitating 
earher inItiatIOn of anttretroviral therapy. I 
. Rapid HIV tests currently in usc arc commonly third-gen-
eraMn tests that detect HIV antibodies (Abs). These rapid tests 
are used at POC to diagnose HI V infection in children older than 
18 months of age and adults. In children younger than 18 months 
of age, reactive third-generation rapid tests indicate HIV exposure 
(ie , babies born to HI V- infected women) rather than HIV infec-
tion because passively acquired maternal HIV Ab can persist to 18 
months of age. In these younger children, laboratory-based viral 
detection assays such as HIV DNA or RNA polymerase chain reac-
tion or p24 antigen (Ag) tests are required to determine an HIV 
infection starus, causing delays in access to treatment and increased 
morbidity and mortality. 
Determme Combo HfV-1 /2 AgiAb Combo Test (DC) ( Inver-
ness Medical Japan Co .. Ltd .. Tokyo, Japan) is the first fourth-gen-
eration rapid test for detection of both HfV Ab and p24Ag. DC 
is an lmmunochromatographic lest for the qualitative detection of 
HfV Abs and p24Ag in the seroconversion phases of HIV infec-
tion. This test is lI1tendcd for use as a first screening rool in areas 
with limited laboratory infrastrucnlrc because it does not require 
any heat or acid manipulation for immune complex dissociation. 
By vi rtue of its ab ili ty to detect p24Ag, the DC has the potentia l to 
diagnose HIV infection in ch ildren younger than 18 months of age 
at poe, providing an earlier definitive diagnosis of HIV !Ofcetioo 
at a single clinic visit. 
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The p24Ag is diagnostic of HIV infection. but in the pres-
ence of HIV Abs and the resultant immune complex formation, the 
sensi tivity for detecting p24Ag is low unless dissociation by heat or 
aCId denaruration is performed.2 ln adults. the sensitivity of p24Ag 
detection is highest in the early and late stages of HIV infection, 
when H I V ~bs are absent or present in low tilers. respectivt!ly. In 
early HIV mfection in vertically infected infants, maternal HIV 
Abs are present to complex with p24Ag. As maternal HIV Abs 
wane. increasing infant HIV Ab titers wou ld participate in immune 
complex fo rmation . In advanced disease. HIV~infected infants 
with hypogammaglobulinemia (i ncluding low HIV Ab titers) , high 
viral loads, and waning maternal HIV Abs are the likeliest to have 
uncomplexed detectable p24Ag. Theoretically, these infants with 
advanced disease also are the most likely La test false-negative on 
third-generat ion HlV rapid tests because oflow HIV Ab titers . 
In adult , the reported sensitivity and specificity of the DC 
HfV Ab component is 100%,' wi th 95% confidence ,"tervals (CI) 
o f 98% to 100% and 98.2% to 100%, respectively. The sensitivity 
of the p24Ag component is 86.6% (95% CI, 76%- 93 .7%)" The 
performance of the DC in 40 HIV-infected infants aged 3 months or 
younger demonstrated a sensi tivity fo r HIV Ab detection of 100% 
(95% CI, 95.9%- 100%), and for p24Ag detection was 2.5% (95% 
CI. 0.1 %- 14.7%).' No clinical detail s of the single 3-month-old 
infant Identified by the DC p24Ag were recorded. No data of the 
performance of the DC test in older infants and children are availa-
ble. Pl.ITtlcularly those to assess whether it may be useful in specific 
clinical scenarios such as advanced disease. 
This study eva luated the ability of the DC to detect p24Ag 
and to provide a diagnosis of HIV infection at POC in stored sam-
ples from children aged younger than 18 months with known clini-
cal presentations. The performance of the DC in detecting HIV Ab 
in chi ldren younger than 18 months of age and establishing HIV 
infection slatus in older children also was investigated. 
MATERIALS AND METHODS 
The Ethics Committee of the University of Witwatersrand 
approved the study. Data from 2 previ ous study cohorts enrolled 
in 2002 and 2005 , respectively, were reviewed to identify cases 
that met criteria for 4 clinical scenarios representative of children 
III the fie ld presenting for HIV testing.'" A history of H1V 
exposure and clinica l staging of disease progression. according to 
Centers for Disease Control guidelines. were used to ass ign cases 
10 the following scenarios: (I) HIV-exposed, uninfected; (2) HIV-
exposecl H1V-infecled and clinically asymptomatic: (3) HIV-
exposecl HIV-infectecl and symptomatic : and (4) HI V-unexposed. 
Children classified as Centers for DISease Control and Prevention 
clinical stages N and A were considcred clinically asymptomatic 
whereas those classified as Centers for Disease Cont rol and 
Prevention clinical stages Band C were considered symptomal1c,1 
A convenience sample of 202 children with a minimum stored 
plasma or serum samp le volume of 50 ~L was selected. Samples 
were retrieved from the accredited - 80°C slorage facility at 
which they were stored for a period of between 6 and 9 years 
and tested by a single operator in ac,cordance with manufacrurer 
instructions. 
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TABLE 1. Performance of the HIV Ab Component of the DC Rapid Test on HIV-exposed and HIV-unexposed Infants 
Study Population DC HlV Ab Rapid Test Results 
HIV·exposed. HlV·exposed , HN-unexposcd , 
Uninfected Infected Uni nfccted DC Ab"1 Sensitivi tyf DC Ab'l SpecificitY' LR' LR' 
ELISA" ELISA' ELISA" ELISA' ELISA" (95% Cll ELISA' (95% CIl Age (rno) PCR' PCR" PCR'(%) PCR' 
,;6 79 43 0 21 ' (26.6) t5 64/64 LOO (94.3-LOO) 30.7 15/15 LOO (79 .~100 ) 0.00 
>6 to ';18 76 33 31 10' (13.2) 2 40/43 93.0 (81.4-97.6) 62.3 33133 LOO (89 .~100) 0.07 
>lS 47 0 14 30" (63.S) 3 29130 96.7 (S3.3-99.4) 33.S 17117 100 (81.~ 100) 0.00 
Total 202 76 45 61"'(30.2) 20 133/137 97 .1 183.3-99.4) 65/65 100 ( SL~LOO) 
Ab indica tes anwbod.Jes. DC, deLern'lIne com bo. ELISA. enzyme-linked iromunosorbant tU;8DY: LR.likehhood mlJo; ?CR. polymerase chain reaction 9.86ay. 
Superscnpt digits denote numbers of symptomatic children (Centers for Dliease Control and Prevention clinic stage ... B and CI. 
· Poslllve test results. 
'Negative tCJit results. 
=Children In the HJV-e.xposed , unmfecLed category with negaLJ.ve ELISA results had undergone selONVer8ion . 
'Prevalence. 
The reference standard against which the DC p24Ag results 
were compared was the Roche Amplicor HIV-I DNA version 1.5 
(Roche Diab'llOstics Systems, Inc., Branchburg, NJ) viral detection 
assay results. The reference standard against which the DC Ab results 
were compared to diagnose HJV exposure in children aged younger 
than 18 months and H1V infection in older children was the HIV-I / 
HIV-2lTl Plus IMx System (Abbott Diagnostics Division, Wicsbaden, 
Germany) enzyme-linked immunosorbant assay (ELISA). Both refer-
ence standard tests were performed at the time the origi nal study was 
performed. Sensitivity, specificity. and likelihood ratios were calcu-
lated. Likelihood ratios were used instead of predictive values because 
the HIV prevalence in the study differed from that in the field . 
Positive likelihood ratios of > I 0 indicate that positive DC 
Ab resul ts strongly predict fo r the presence of HIV Abs in all age 
groups. Negative likelihood ratios of <0.1 indicate lhat negative DC 
Ab results are strongly correlated with the absence of HIV Abs. 
RESULTS 
The DC was performed on stored samples from 20 (10%) 
HIV-unexposed and 182 (90%) HIV-exposed children, including 61 
HI V-infected children with an overa ll HI V preva lence of 30.2%. 
A summary of patient age, exposure/infection status, test results, 
sensitivity, and specificity are presented in Table I. The DC Ab 
rapid test results were consistent with Ihe HIV ELISA results for 
all but 4 children when lhe DC Abs returned false-negalive results 
for 2 HrV-exposed, uninfected 7-month-old children and in 2 HIV-
infected children, I who was 7 month s old and symptomatic and I 
who was 23 mon ths old and asymptomatic. The DC Ab component 
was 100% sensitive in infants aged 6 months and younger. The DC 
Ab component of the test demonstrated no false-positive resu lts, 
hence the overall specificity of 100% with 95% CI of 8 1.6% to 
100% (Table I J. 
Of the 61 HIV-infected in fa nts tested, the DC p24Ag was 
reactive in only a 3-month-old clinically symptomatic infant, re-ult-
ing in sensitivity for detecti on of HIV infecti on of I. 7% (95% CI. 
0.3%- 8.9%). The other 12 clin ica lly symptomatic infected children 
aged younger than 18 months tested negative for the DC p24Ag. 
No false-positive DC p24Ag results were obtained, resulting 
in a spec ificity of 100% (95% CI, 97.3%-100% ). 
DISCUSSION 
Child health programs require rapid HIV tests to detect HIV 
exposure, to exclude HIV infection in infants, and to diagnose HI V 
© 2013 Lippillcol/ Williams & Wilkins 
infection status in older children. In theory, a fourth-generation rapid 
HI V test should add the option of a POC test for the diagnosis of HTV 
infection in in fants to this repertoire. This is the first study to explore 
the performance of the DC test in the context of clinical scenarios 
expected to present in child health programs in low-resource settings. 
The DC rapid test failed to detect p24Ag in 98% of HTV-
infecled infants. These findings are si mi lar to the results obtained 
in the younger cohort of infants tested, including the observation 
that the only infant testing p24Ag-positive was also 3 months of 
age' However, even at 3 months of age, the sensitivity of the p24Ag 
component in detecting HIV infection is < 10% (data not shown). 
Among the 12 clinically ymptomatic children was a 
6.9-month-old infected infant who tested DC Ab-negative, con-
tradicting our hypothesis that the DC would be able to detect an 
increase in unbound p24Ag in the setting of waning maternal HIV 
Abs and late-stage in fant HIV infection. 
The DC HIV Ab component is comparable with other third-
generation HTV rapid tests to screen for HIV exposure in infants 
younger than 6 months of age. For older children, the DC tcst sensi-
tivity is <99%, which is recommended by the World Health Organi-
zation (Table I) ' The inabil ity of the DC Ab component to detect 
HIV Abs in the 2 HIV-exposed 7-month-old un infected in fa nts may 
be because these infants were in the process of seroreverting. 
Limitations of this study include a smal l sample size in each 
clinical and age group category and prolonged storage of samples. 
However, HIV Abs were detected in 133 (97%) of 137 cases, sug-
gesting limited. if any, Ab degradation. Viral p24Ag is reportedly 
stable in samples stored for 10 years. ' 
Recently, the performance of POC p24Ag detection on a 
dipstick to diagnose HIV infection in infants has been dramatically 
improved by devices that separate plasma from whole blood and 
usc heat 10 disnlpt p24Ag immune complexes before testing." '" 
A sensitivity of 96% (95% CI. 8SO/.,..99%) and specificity of 99% 
(95% CI, 98%- 100%) have been demonstrated in the laboralOry 
and field testing results arc awaited. 
The fourth-generation DC rapid test cannot be recommended 
for POC diagnosis of HIV infection in infants , even at 3 months of 
age or during advanced-stage disease. The sensi tivity of the DC 
for detection of HIV exposure and diagnosis of HIV infection in 
ch i Idren is no better than that of third-generation HJV rapid test . 
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